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Abstract: Muraymycins are a subclass of naturally occurring nucleoside antibiotics with promising
antibacterial activity. They inhibit the bacterial enzyme translocase I (MraY), a clinically yet unexploited
target mediating an essential intracellular step of bacterial peptidoglycan biosynthesis. Several
structurally simplified muraymycin analogues have already been synthesized for structure–activity
relationship (SAR) studies. We now report on novel derivatives with unprecedented variations
in the nucleoside unit. For the synthesis of these new muraymycin analogues, we employed a
bipartite approach facilitating the introduction of different nucleosyl amino acid motifs. This also
included thymidine- and 5-fluorouridine-derived nucleoside core structures. Using an in vitro
assay for MraY activity, it was found that the introduction of substituents in the 5-position of the
pyrimidine nucleobase led to a significant loss of inhibitory activity towards MraY. The loss of
nucleobase aromaticity (by reduction of the uracil C5-C6 double bond) resulted in a ca. tenfold
decrease in inhibitory potency. In contrast, removal of the 2′-hydroxy group furnished retained
activity, thus demonstrating that modifications of the ribose moiety might be well-tolerated. Overall,
these new SAR insights will guide the future design of novel muraymycin analogues for their potential
development towards antibacterial drug candidates.
Keywords: antibiotics; natural products; nucleoside analogues; structure–activity relationships
1. Introduction
The increasing number of bacterial infections with strains that are resistant against established
antibiotics are a major challenge in current and future clinical healthcare [1,2]. For the development
of new antimicrobial drug candidates, cross resistances with established antibiotics are a central
concern. Therefore, novel targets and yet unexploited modes of action need to be identified [3].
A promising target not yet addressed by clinically established classes of antibiotics is the bacterial
enzyme MraY (translocase I) which mediates a key step in the intracellular stages of bacterial cell
wall biosynthesis [4–6]. MraY catalyzes the first membrane-associated step in the cytosolic stage of
peptidoglycan synthesis, i.e., the formation of the membrane-bound intermediate lipid I by reaction of
UDP-MurNAc pentapeptide (’Park’s nucleotide’) with the isoprenoid membrane anchor undecaprenyl
phosphate (Scheme 1) [7–13].
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Scheme 1. Reaction of Park’s nucleotide 1 with undecaprenyl phosphate 2 yielding lipid I 3, 
catalyzed by MraY (translocase I). UDP = uridine diphosphate, UMP = uridine monophosphate. The 
exact composition of the pentapeptide moiety varies among different bacteria [12]. 
Nucleoside antibiotics are naturally produced secondary metabolites acting as MraY inhibitors. 
Several subclasses such as muraymycins, mureidomycins, tunicamycins, liposidomycins, and 
capuramycins have been reported [13–16]. Our research on nucleoside antibiotics mainly focusses on 
muraymycins which were isolated from Streptomyces sp. as a set of 19 structurally varying natural 
products [13,17]. Recently, several new members of this subclass have been reported [18]. 
Muraymycins can be divided into four groups (A–D, Figure 1). They share a joint backbone 
structure, i.e., a uridine-derived nucleosyl amino acid ('glycyluridine', GlyU) motif and a 
urea-containing peptide moiety, but vary in the substitution pattern at the central L-leucine unit and 
in the presence of aminoribosyl substituents in the 5'-position. 
 
Figure 1. Structures of selected naturally occurring muraymycins 4–7 [18–20]. 
In the A- and B-series (e.g., muraymycins A1 4 and B8 5, Figure 1), lipophilic side chains are 
present which are connected to the backbone as fatty acid esters of β-hydroxylated L-leucine. Such 
motifs are not found in the C- and D-series congeners (e.g., muraymycins C4 6 and D2 7, Figure 1). 
Different aminoribosyl substituents (X in Figure 1) at the GlyU core structure are present in most 
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Figure 1. Structures of selected naturally occurring muraymycins 4–7 [18–20].
In the A- and B-series (e.g., muraymycins A1 4 and B8 5, Figure 1), lipophilic side chains
are present which are connected to the backbone as fatty acid esters of β-hydroxylated L-leucine.
Such motifs are not found in the C- and D-series congeners (e.g., muraymycins C4 6 and D2 7, Figure 1).
Different aminoribosyl substituents (X in Figure 1) at the GlyU core structure are present in most
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naturally occurring muraymycins. Structures containing hydroxy groups in the 5′-position (e.g., 6) are
discussed to be hydrolysis products formed in the isolation and purification process of the natural
products [19–21].
In 2016, an X-ray co-crystal structure of the natural product muraymycin D2 7 in complex with
MraY from Aquifex aeolicus was reported by Chung et al. [22,23]. These structural insights into the target
interaction of muraymycins allowed an identification of possible key interactions which were used to
rationalize the design of synthetic muraymycin analogues for SAR studies [24]. A comparison of the
aforementioned co-crystal structure with the previously reported crystal structure of the ligand-free apo
enzyme [25] revealed a large conformational change due to inhibitor binding, hinting to a pronounced
conformational plasticity of MraY. In this context, the formation of a well-defined binding pocket for the
uridine-derived GlyU moiety was observed (Figure 2). This was regarded as one of the main reasons
for the high binding affinity of naturally occurring nucleoside antibiotics despite their structural
deviation from the natural substrate, i.e., UDP-MurNAc pentapeptide 1 [22,23,25]. Very recently,
a more comprehensive model for MraY binding of diverse classes of nucleoside antibiotics, again based
on X-ray crystallographic studies, has been reported [26].
Figure 2. X-ray co-crystal structure of MraY from Aquifex aeolicus in complex with muraymycin D2 7
(PDB 5CKR) [22,23]: protein-inhibitor interactions at the GlyU binding site (hydrocarbon scaffold of
inhibitor 7 in light blue; orange arrow: well-defined uracil binding pocket; green arrow: ribose moiety
of the uridine-derived GlyU unit showing no significant interactions of 2′-OH and 3′-OH).
Synthetic access to the naturally occurring muraymycins is challenging due to structural features
such as the non-proteinogenic amino acid L-epicapreomycidine, the aminoribosylated GlyU moiety
and the (3S)-3-hydroxy-L-leucine unit. Total syntheses of some naturally occurring muraymycins
have been reported though [13,27–29], and synthetic routes towards crucial structural motifs have
been developed [30–33]. Both for potential applications and for more straightforward SAR studies,
several simplified muraymycin analogues have been designed [34–38]. By comparison of different
natural products and synthetic analogues with long alkyl side chains, it was shown that increased
lipophilicity improves antibacterial activities (MIC values), but has only a minor effect on MraY
inhibition [17,20,39,40]. This is probably owed to an improved cellular uptake of lipophilically decorated
muraymycins. Through design of simplified analogues, the terminal urea dipeptide motif [40] as
well as the 5′-O-aminoribosyl substituent [21,39] were identified to mediate key interactions in MraY
inhibition. However, synthetically obtained 5′-defunctionalized (′5′-deoxy’) muraymycin C4 that
was reported by our group [38] was found to still inhibit MraY in the nM range, even though most
naturally occurring muramycins are MraY inhibitors with pM activities [39]. The replacement of
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(3S)-3-hydroxy-L-leucine with L-leucine resulted in a ~25-fold loss of activity [41], but that implied
that such simplified analogues may still be employed in SAR studies. The exact structure of the
amino acid side chains in the urea dipeptide moiety seems to only have limited impact on MraY
inhibition [21]. These findings led to the design of simplified analogues containing L-lysine instead of
L-epicapreomycidine (e.g., analogue 8, Figure 3, MraY inhibition: IC50 = 2.5 µM), thus further reducing
synthetic effort [24]. Regarding the stereochemistry of the nucleoside moiety, the naturally occurring
(6′S)-configuration was found to be preferred. If a 5′-hydroxy group was present, at least either C-5′ or
C-6′ needed to have their naturally occurring configuration in order to retain good inhibitory activity
towards MraY in vitro [41].
Figure 3. Structures of previously reported 5′-deoxy muraymycin analogues 8–10 [24] and the
previously reported protecting group-containing analogues 11 and 12 (PMB = p-methoxybenzyl,
TBDMS = tert-butyldimethylsilyl) [34].
It was also attempted to synthesize and study analogues bearing the aminoribosyl substituent
(X in Figure 1) at different positions of the muraymycin scaffold. This led to compounds 9 and 10
(with 10 serving as a reference, Figure 3) which were modified at the N-3 position of the uracil base.
However, these analogues showed no inhibitory activity against MraY [24]. Remarkably, previously
reported simplified analogues 11 and 12 (which still contained synthetic TBDMS and, in case of 12,
PMB protecting groups, Figure 3) had been described to be antibacterially active MraY inhibitors,
in spite of the modification of the uracil base in compound 12 [34].
Overall, the X-ray co-crystal structure (Figure 2) and the results with analogues 9 and 10 (Figure 3)
suggest that some structural variations in the muraymycin nucleoside moiety might significantly
hamper MraY inhibition. This is particularly the case for modifications of the uracil base with
respect to the well-defined uracil binding pocket of MraY (Figure 2, orange arrow). In contrast,
binding of the GlyU ribose moiety appears to be far less specific, with the X-ray co-crystal structure
showing no significant interactions of the 2′-OH and 3′-OH groups (Figure 2, green arrow). However,
the pronounced conformational plasticity of MraY (vide supra) might generally enable its adaptation
to structural variations of inhibitors, which would be very hard to predict from the (inherently static)
X-ray co-crystal structure. In this work, we have therefore decided to experimentally probe the SAR of
the muraymycin nucleoside moiety by introducing structural changes to it which were supposed to
be more subtle than the ones in analogues 9–12 (cf. Figure 3). These considerations have led to the
design of the following target compounds (Scheme 2), which were based on the previously described
5′-defunctionalized muraymycin analogue 8 (vide supra): (i) a derivative 13 containing 5-fluorouracil
as a nucleobase; (ii) 2′-deoxy analogue 14; (iii) thymidine-derived analogue 15. This would enable us to
systematically study both the influence of different C-5 substituents of the pyrimidine base (including
the potential electronic effect of fluorine) and the significance of the 2′-functionalization of the ribose
moiety. Furthermore, we have also envisioned to investigate a fourth target structure to evaluate
the relevance of nucleobase aromaticity, i.e., derivative 16 having non-aromatic 5,6-dihydrouracil as
a nucleobase (Scheme 2). Overall, target structures 13–16 were chosen based on the rationale that
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multiple SAR insights (regarding C-5-substitution, ribose modification, and nucleobase aromaticity)
should be obtained with reasonable synthetic effort.
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should be accessible by reductive amination of the peptide-derived aldehyde 17 with different nucle syl
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The synthesis of nucleosyl amino acids 18–20 was performed in analogy to the previously reported
stereocontrolled synthesis of other uridi e-derived 5’-deoxy nucleosyl amin acids (Scheme 3) [31].
Commercially available nucleosides 5-fluorouridine 21, 2’-deoxyuridine 22 and thymidine 23 were
fully TBDMS-protected to give persilylated nucleosides 24–26 (yields 62%–97%). The protocols for
subsequent selective 5’-O-desilylation had to be modified with respect to the different nucleoside
structures. Thus, for 5-fluorouridine derivative 24, deprotection towards product 27 with aqueous
TFA [43] proceeded with good yield (69%) and regioselectivity. For 25 and 26, however, reduced steric
differentiation of the 3’- and 5’-positions (due to the absence of a 2′-O-TBDMS moiety adjacent to
the 3′-position) led to poor selectivity under similar conditions. Therefore, an alternative method
using milder acidic conditions [44] was applied: Hydrochloric acid was generated in situ by reaction
of acetyl chloride with methanol at lower temperatures. This protocol furnished 5’-O-desilylated
products 28 and 29 in yields of 65% and 59%, respectively. Nucleosides 27–29 were then oxidized to the
corresponding 5′-aldehydes 30–32 in 92% to quantitative yields. Subsequent Wittig–Horner reaction of
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these aldehydes with phosphonate 33 [31] gave Z-configured didehydro nucleosyl amino acids 34–36.
For 35 and 36, this transformation proceeded with good yields of 72% and 77%, respectively. In the case
of the 5-fluorouridine derivative 34, a low yield of 14% was obtained (Scheme 3). This was attributed
to the increased acidity of the 5-fluorouracil imide 3-NH, caused by the electron-withdrawing fluorine
substituent. Hence, the imide is supposed to (at least partially) protonate the phosphonate anion,
thus resulting in incomplete conversion and potentially also partial decomposition of unconverted
aldehyde 30. Using an excess of KHMDS to avoid this side reaction resulted in a loss of stereoselectivity,
probably due to base-mediated isomerization of the C-5′-C6′ double bond (reactions not shown).
We had studied before if 3-N-protection is a viable option for this synthetic route, but results were
disappointing mainly due to difficult deprotection reactions [31]. Hence, no further optimization of
the synthesis of 34 was attempted and it was decided instead to proceed with the obtained material.
For all didehydro nucleosyl amino acids 34–36, the assignment of the Z-stereochemistry of the C-5′-C6′
double bond was based on precedent [31] and 1H NMR spectroscopic data (i.e., characteristic chemical
shifts of the 5′-H [31]).
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Scheme 3. Stereocontrolled synthesis of (6′S)-configured nucleosyl amino acids 18–20.
The next step was the asymmetric hydrogenation of 34–36 using the chiral (S,S)-Me-DUPHOS-Rh(I)
catalyst 37 [31,45] (Scheme 3). It had been proven before that this catalyst electiv ly fu nishes
L-amino acids from Z-didehydro amino acid precursors [31,46,47], thus giving rise to the formation of
N-Cbz-protected (6′S)-configured nucleosyl amino acids 38–40 in yields of 51%–95%. The formation of
the unwanted (6′R)-epimer was not observed in any of these reactions. Finally, Cbz deprotection under
transfer hydrogenation conditions (to avoid reduction of the pyrimidine C-5-C-6 double bond [31])
afforded (6′S)-nucleosyl amino acids 18–20 in yields of 88%–98% (Scheme 3).
The synthesis of the peptide-aldehyde unit 17, based on a solid phase-supported approach,
has been performed as recently reported [42]. Thus, the stage was set for the preparation of target
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structures 13–15 (Scheme 4). Nucleosyl amino acids 18–20 were connected with peptide-aldehyde 17
by reductive amination. This transformation had been described before as a key step in the synthesis
of muraymycin analogues [24,31,38]. Subsequent global acidic deprotection using 80% aqueous TFA
and HPLC purification afforded target compounds 13–15 as their bis-TFA salts in 13%–25% yields over
two steps from 18–20 (Scheme 4).
Molecules 2019, 24, x FOR PEER REVIEW  7 of 23 
 
The synthesis of the peptide-aldehyde unit 17, based on a solid phase-supported approach, has 
been performed as recently reported [42]. Thus, the stage was set for the preparation of target 
structures 13–15 (Scheme 4). Nucleosyl amino acids 18–20 were connected with peptide-aldehyde 17 
by reductive amination. This transformation had been described before as a key step in the synthesis 
of muraymycin analogues [24,31,38]. Subsequent global acidic deprotection using 80% aqueous TFA 
and HPLC purification afforded target compounds 13–15 as their bis-TFA salts in 13%–25% yields 
over two steps from 18–20 (Scheme 4). 
 
Scheme 4. Synthesis of target structures 13–15. 
For the synthesis of target compound 16 containing 5,6-dihydrouracil as a nucleobase, our 
previously developed solution-phase tripartite approach was applied [13,38]. The nucleosyl amino 
acid building block was prepared by hydrogenation of 41 [31] to give concomitant Cbz cleavage and 
reduction of the uracil-C5-C6 double bond, affording 42 in 96% yield (Scheme 5). This reduction of 
the uracil nucleobase can otherwise be observed as a side reaction during the hydrogenolytic 




























































































Scheme 5. Synthesis of target structure 16. 
Scheme 4. Sy t t str ctures 13–15.
For the synthesis target compound 16 containing 5,6- ihydrouracil as a nucle base,
our previously developed solution-phase tr partite appro ch was applied [13,38]. The nucleosyl
amino acid building block was prepared by hydroge ation of 41 [31] to give concomitant Cbz cle vage
and reduction of the uracil-C5-C6 double bond, affording 42 in 96% yield (Scheme 5). This reduction
of the uracil nucleobase can otherwise be observed as a side reaction during the hydrogenolytic
deprotection of nucleosyl amino acids [31].
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Introduction of the propyl linker and the leucine moiety was achieved by reductive amination of
42 with aldehyde 43 [24,34], furnishing 44 in 58% yield (Scheme 5). After hydrogenolytic Cbz cleavage
(product 45, quantitative yield), urea dipeptide building block 46 [24,41] was employed in a peptide
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coupling step to construct the full-length muraymycin scaffold. This was followed by global acidic
deprotection and HPLC purification to give target compound 16 (as its bis-TFA salt) in 32% yield over
two steps from 45 (Scheme 5).
2.2. Biological Evaluation
Target structures 13–16 were tested for their inhibitory potential towards the bacterial target
enzyme MraY in vitro. For these studies, we used an established fluorescence-based assay for
MraY activity, which employs a dansylated version of Park’s nucleotide 1 and MraY from S. aureus
(heterologously overexpressed in E. coli) [18,39,48–52]. The obtained inhibitory activities (IC50 values,
also see Supplementary Materials Figures S1–S4, for measured data and inhibition curves) are listed in
Table 1, including the potency of previously reported reference compound 8 [24,41]. As target structures
13 and 15 turned out to be nearly inactive as MraY inhibitors in the relevant concentration range
(≤100 µM), we also tested them at a significantly higher concentration (1 mM, Table 1). Muraymycin
analogues 13–16 were also investigated for their antibacterial activities in cellulo against E. coli, but were
inactive (MIC > 50 µg/mL).
Table 1. In vitro inhibitory activities of muraymycin analogues 13–16 against MraY from S. aureus.
Compound R Base IC50 [µM]1
13 OH >100(49% inhibition @1 mM)
14 H 4.6 ± 1.8
15 H >100(38% inhibition @1 mM)
16 OH 27 ± 8
8 OH 2.5 ± 0.6
1 A crude membrane preparation of MraY from S. aureus, heterologously overexpressed in E. coli, was used.
Measurements for significantly active compounds (IC50 < 100 µM) were carried out in triplicates, for weakly active
compounds (IC50 > 100 µM) in duplicates. Data for significantly active compounds are given as mean value ±
standard deviation. For weakly active compounds, percentage of inhibition at 1 mM is also listed.
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3. Discussion
The synthesis of the target structures 13–16 was successfully accomplished. For 13–15, we have
applied a recently reported novel approach which is based on the solid phase-supported synthesis
of the peptide–aldehyde unit 17, which was then connected with a nucleosyl amino acid building
block 18–20 (Scheme 2) [42]. Thus, we mainly had to focus on the preparation of 18–20, which
was performed using an established route with Wittig–Horner reaction and subsequent asymmetric
hydrogenation as key steps for the stereoselective construction of the amino acid motif [31]. It was thus
demonstrated that this protocol is applicable for the introduction of different nucleoside core structures.
In contrast to this bipartite strategy, target compound 16 was prepared using our previously employed
solution-phase tripartite approach [13,38]. This enabled a direct comparison of both routes. With
respect to the late-stage introduction of the nucleosyl amino acid moiety, the solid phase-supported
bipartite synthesis (Schemes 3 and 4) appears to be superior and more efficient for studies on analogues
with varying nucleoside structures.
The in vitro assay for inhibitory activities of 13–16 towards the bacterial target protein MraY
provided highly interesting, unprecedented SAR insights. Compound 13 differs from reference
compound 8 only in the formal substitution of the uracil-5-H with a fluorine atom. Nevertheless,
this minor structural alteration leads to a nearly complete loss of inhibitory activity (Table 1). In contrast,
the comparison of 2′-deoxyuridine-derived analogue 14 with 8 reveals a full retention of inhibitory
activity (within the error margin of the assay). This suggests that structural variations in the ribose
moiety appear to be much better tolerated than nucleobase modifications. Accordingly, when an
additional 5-methyl substituent was formally introduced into the structure of 14 (i.e., thymidine
analogue 15), the inhibitory activity was nearly completely lost again. The only partially tolerated
modification of the pyrimidine base studied in this work was the reduction of the C5-C6 double bond,
as 16 was only ca. tenfold less active than 8.
These results are in good agreement with the insights obtained from the X-ray crystal structure
of MraY from Aquifex aeolicus in complex with muraymycin D2 7 [22,23] (vide supra, Figure 2).
The well-defined binding pocket for the uracil base indeed seems to preclude the introduction of
substituents into this moiety. In the case of 5-fluoro substitution, it is not fully clear though if the
loss of inhibitory activity is a result of steric hindrance or electronic effects (with respect to the
strong electron-withdrawing nature of fluorine). Key interactions in the uracil binding pocket include
hydrogen bonding with Lys70, Asp196, and Asn255 (Figure 2). The formation and/or strength of
these hydrogen bonds might be hampered by the electron deficiency of the 5-fluorouracil moiety.
The non-aromatic nucleobase in analogue 16 is probably not sterically hindered, but cannot undergo
the same π–π interaction with Phe262 as uracil, thus resulting in a moderate loss of activity. However,
the retention of inhibitory activity for 2′-deoxy congener 14 could also be predicted from the X-ray
crystal structure as it had indicated no obvious interaction of the 2′-hydroxy group (vide supra,
Figure 2). Overall, our findings demonstrate that X-ray crystal structures of MraY-inhibitor complexes
appear to be excellent starting points for the structure-based design of new inhibitors, at the very least
with respect to variations in the uridine-derived core unit.
The lack of antibacterial activities of target structures 13–16 in cellulo was expected. With respect to
their potential to inhibit MraY, analogues 14 and 16 were the only candidates for showing antibacterial
activity anyway. As part of our previous work on muraymycins, we had shown that there might
be a ’threshold’ of inhibitory activity towards MraY for observing antibacterial potency in cellulo,
concluding that a low-nM (or stronger) inhibitory potency against MraY might be a prerequisite for
sufficient antibacterial activity [24,41]. As 14 and 16 were not within this activity range as MraY
inhibitors, their non-activity in cellulo was in good agreement with this hypothesis. It should be
pointed out that the main goal of this work was to obtain new SAR insights on MraY inhibition and
not to optimize muraymycin analogues for improved antibacterial potencies. The latter can probably
be achieved at a later stage by making such muraymycin analogues more lipophilic, as their polar
scaffold surely impairs cellular uptake.
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4. Materials and Methods
4.1. Synthesis of Muraymycin Analogues
General methods: All chemicals were purchased from standard suppliers. Reactions involving
oxygen and/or moisture sensitive reagents were carried out under an atmosphere of nitrogen or argon
using anhydrous solvents. Anhydrous solvents were obtained in the following manner: THF and
MeCN were dried with a solvent purification system (MBRAUN MB SPS 800). Pyridine and i-PrOH
were dried over CaH2 and distilled. MeOH was dried over activated molecular sieves (3 Å) and
degassed. All of the thus obtained solvents were stored over molecular sieves (4 Å; in case of MeOH 3
Å). All other solvents were of technical quality and distilled prior to use, and deionized water was used
throughout. Column chromatography was carried out on silica gel 60 (0.040–0.063 mm, 230–400 mesh
ASTM, VWR) under flash conditions except where indicated. TLC was performed on aluminum plates
precoated with silica gel 60 F254 (VWR). Visualization of the spots was carried out using UV light
(254 nm) and/or staining under heating (H2SO4 staining solution: 4 g vanillin, 25 mL conc. H2SO4,
80 mL AcOH and 680 mL MeOH; KMnO4 staining solution: 1 g KMnO4, 6 g K2CO3 and 1.5 mL
1.25 M NaOH solution, all dissolved in 100 mL H2O; ninhydrin staining solution: 0.3 g ninhydrin,
3 mL AcOH and 100 mL 1-butanol; bromocresol green staining solution: 0.1 g bromocresol green,
500 mL EtOH, 5 mL 0.1 M aqueous NaOH solution). Semipreparative HPLC was performed on a
VWR-Hitachi system equipped with an L-2300 pump, an L-2200 autosampler, an L-2300 column oven
(24 ◦C), an L-2455 Diode Array Detector (DAD) and a LiChroCartTM column (10 × 250 mm) containing
reversed phase silica gel Nucleodur™ 100-5 C18ec (10 µm) purchased from Macherey-Nagel. Method
1: eluent A water (+0.1% TFA), eluent B MeCN (+0.1% TFA); 0–15 min gradient of B (10%–20%),
15–25 min gradient of B (20%–40%), 25–32 min gradient of B (40%–100%), 32–40 min 100% B, 40–41
min gradient of B (100%–30%), 41–45 min 30% B; flow 2 mL/min. Method 2: eluent A water (+0.1%
TFA), eluent B MeCN (+0.1% TFA); 0–15 min gradient of B (20%–30%), 15–25 min gradient of B
(30%–40%), 25-32 min gradient of B (40%–80%), 32–40 min 80% B, 40–41 min gradient of B (80%–30%),
41–45 min 30% B; flow 2 mL/min. Method 3: eluent A water, eluent B MeCN, 0–25 min gradient
of B (5%–50%), 25–40 min gradient of B (50%–100%), 40–45 min 100% B, 45–50 min gradient of B
(100%–5%), flow 5 mL/min. 500 MHz-1H, 126 MHz-13C, as well as 202 MHz-31P NMR spectra were
recorded on a Bruker UltraShieldTM-500 spectrometer. 376 MHz-19F NMR spectra were recorded on a
Bruker UltraShieldTM-400 spectrometer. 300 MHz-1H and 76 MHz-13C NMR spectra were recorded
on a Bruker Fourier 300 spectrometer. All 13C and 19F NMR spectra are 1H-decoupled. All spectra
were recorded at room temperature except where indicated and were referenced internally to solvent
reference frequencies wherever possible. Chemical shifts (δ) are quoted in ppm and coupling constants
(J) are reported in Hz. Assignment of signals was carried out using H,H-COSY, HSQC, and HMBC
spectra obtained on the spectrometers mentioned above. The numbering of atoms of muraymycin
target structures is depicted in the Supplementary Materials Figure S5. Mass spectra were measured
on a Finnigan Surveyor MSQ Plus mass spectrometer. For ESI measurements in the positive mode,
solutions in MeOH were used. High resolution mass spectra were measured on a Thermo Scientific Q
Exactive Orbitrap mass spectrometer with ESI ionization mode and on a Finnigan sectorfield mass
spectrometer type MAT 95S with chemical ionization (CI).
5-Fluorouridine-derived muraymycin analogue (13): Nucleosyl amino acid ester 18 (35 mg,
58 µmol) was dissolved in THF (3 mL), and a solution of aldehyde 17 [42] (46 mg, 75 µmol) in
THF (3 mL) was added. The reaction mixture was stirred over molecular sieve (3 Å) at rt for 24 h.
NaBH(OAc)3 (33 mg, 0.16 mmol) and Amberlyst 15TM (3.4 mg, 11 µmol) were added and stirring was
continued at rt for 24 h. The reaction mixture was filtered and the residue was washed with EtOAc
(150 mL). The combined filtrates were washed with sat. NaHCO3 solution (100 mL) and brine (50
mL). The aqueous layer was extracted with EtOAc (3 × 100 mL). The combined organics were dried
over Na2SO4 and the solvent was evaporated under reduced pressure. The resultant crude product
was purified by column chromatography (98:2→95:5, CH2Cl2-MeOH) to give the fully protected
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muraymycin analogue as a colorless solid. This was dissolved in aq. TFA (80%, 4.6 mL) and stirred at
rt for 24 h. The reaction mixture was then diluted with water (12 mL) and the solvent was evaporated
under reduced pressure. The resultant crude product was purified by semipreparative HPLC (method
1) to give 13 (bis-TFA salt) as a colorless foam (11 mg, 25% over 2 steps from 18). 1H NMR (500 MHz,
D2O): δ [ppm] = 0.83 (d, J = 6.0 Hz, 3H, Leu-5-H), 0.88 (d, J = 5.7 Hz, 3H, Leu-5-H), 0.89 (d, J = 6.9 Hz,
3H, Val-4-H), 0.93 (d, J = 6.9 Hz, 3H, Val-4-H), 1.33–1.48 (m, 2H, Lys-4-H), 1.50–1.70 (m, 6H, Lys-3-Ha,
Lys-5-H, Leu-3-H, Leu-4-H), 1.73–1.87 (m, 1H, Lys-3-Hb), 1.85–1.92 (m, 2H, 2”-H), 2.10–2.16 (m, 1H,
Val-3-H), 2.23–2.33 (m, 1H, 5′-Ha), 2.39–2.44 (m, 1H, 5′-Hb), 2.96 (t, J = 7.6 Hz, 2H, Lys-6-H), 3.06 (t, J =
7.6 Hz, 2H, 1”-H), 3.20–3.29 (m, 2H, 3”-Ha, 3”-Hb), 3.85–3.90 (m, 1H, 6′-H), 4.03 (dd, J = 12.3, 6.3 Hz,
1H, 3′-H), 4.05 (d, J = 5.4 Hz, 1H, Val-2-H), 4.09 (dd, J = 8.5, 5.4 Hz, 1H, Lys-2-H), 4.14 (ddd, J = 9.8, 6.3,
2.8 Hz, 1H, 4′-H), 4.23 (dd, J = 10.1, 5.0 Hz, 1H, Leu-2-H), 4.35 (dd, J = 5.7, 3.8 Hz, 1H, 2′-H), 5.73 (d, J =
3.8 Hz, 1H, 1′-H), 7.81 (d, J = 6.3 Hz, 1H, 6-H). 13C NMR (126 MHz, D2O): δ [ppm] = 17.02 (Leu-C-5),
18.55 (Leu-C-5), 20.70 (Val-C-4), 22.08 (Lys-C-4), 22.15 (Val-C-4), 24.44 (Lys-C-5), 25.70 (C-2”), 26.31
(Leu-C-4), 30.02 (Val-C-3), 30.83 (Lys-C-3), 32.91 (C-5′), 36.01 (C-3′), 39.28 (Lys-C-6), 39.55 (Leu-C-3),
44.36 (C-1”), 52.65 (Leu-C-2), 54.11 (Lys-C-2), 58.95 (Val-C-2), 59.70 (C-6′), 72.83 (C-2′), 72.89 (C-3′),
79.96 (C-4′), 91.38 (C-1′), 116.45 (d, JCF = 291.4 Hz, TFA-CF3), 126.45 (d, JCF = 34.8 Hz, C-6), 140.76 (d,
JCF = 233.7 Hz, C-5), 150.02 (C-2), 159.36 (urea-C=O), 159.55 (C-4), 163.07 (d, JCF = 35.8 Hz, TFA-COO),
172.02 (C-7′), 174.98 (Leu-C-1), 175.48 (Lys-C-1), 176.80 (Val-C-1). 19F NMR (376 MHz, D2O): δ [ppm]
= −166.24 (1F, 5-F), −75.59 (6F, TFA-CF3). MS (ESI+): m/z = 761.5 [M + H]+. HRMS (ESI+): calcd.:
761.3840 [M + H]+, 783.3659 [M + Na]+, found: 761.3843, 783.3646. HPLC (semipreparative): tR = 24.2
min (method 1).
2’-Deoxyuridine-derived muraymycin analogue (14): Nucleosyl amino acid ester 19 (12.6 mg,
27.6 µmol) was dissolved in THF (1.7 mL), and a solution of aldehyde 17 [42] (17 mg, 28 µmol) in
THF (1.7 mL) was added. The reaction mixture was stirred over molecular sieve (3 Å) at rt for 24 h.
NaBH(OAc)3 (12.3 mg, 58.0 µmol) and Amberlyst 15TM (1.9 mg, 5.5 µmol) were added and stirring
was continued at rt for 24 h. The reaction mixture was filtered and the residue was washed with EtOAc
(150 mL). The combined filtrates were washed with sat. NaHCO3 solution (100 mL) and brine (50 mL).
The aqueous layer was extracted with EtOAc (3 × 100 mL). The combined organics were dried over
Na2SO4 and the solvent was evaporated under reduced pressure. The resultant crude product was
purified by column chromatography (98:2→96:4→95:5, CH2Cl2-MeOH) to give the fully protected
muraymycin analogue as a colorless solid. This was dissolved in aq. TFA (80%, 1.3 mL) and stirred at
rt for 24 h. The reaction mixture was then diluted with water (12 mL) and the solvent was evaporated
under reduced pressure. The resultant crude product was purified by semipreparative HPLC (method
1) to give 14 (bis-TFA salt) as a colorless foam (3.5 mg, 13% over 2 steps from 19). 1H NMR (500 MHz,
D2O): δ [ppm] = 0.84 (d, J = 6.0 Hz, 3H, Leu-5-H), 0.89 (d, J = 6.0 Hz, 3H, Leu-5-H), 0.90 (d, J = 6.6 Hz,
3H, Val-4-H), 0.93 (d, J = 6.9 Hz, 3H, Val-4-H), 1.35–1.46 (m, 2H, Lys-4-H), 1.50–1.69 (m, 6H, Lys-3-Ha,
Lys-5-H, Leu-3-H, Leu-4-H), 1.72–1.80 (m, 1H, Lys-3-Hb), 1.85–1.91 (m, 2H, 2”-H), 2.10–2.17 (m, 1H,
Val-3-H), 2.20 (ddd, J = 15.1, 10.4, 6.0 Hz, 1H, 5′-Ha), 2.33 (ddd, J = 14.5, 7.3, 5.7 Hz, 1H, 2′-Ha), 2.38
(ddd, J = 14.8, 6.9, 2.8 Hz 1H, 5′-Hb), 2.45–2.51 (m, 1H, 2′-Hb), 2.96 (t, J = 7.6 Hz, 2H, Lys-6-H), 3.04
(t, J = 7.6 Hz, 2H, 1”-H), 3.19–3.32 (m, 2H, 3”-Ha, 3”-Hb), 3.88 (t, J = 6.3 Hz, 1H, 6′-H), 4.03 (ddd, J
= 10.4, 5.0, 2.8 Hz, 1H, 4′-H), 4.05 (d, J = 5.4 Hz, 1H, Val-2-H), 4.09 (dd, J = 8.8, 5.7 Hz, 1H, Lys-2-H),
4.23 (dd, J = 9.8, 4.7 Hz, 1H, Leu-2-H), 4.28–4.32 (m, 1H, 3′-H), 5.85 (d, J = 8.2 Hz, 1H, 5-H), 6.16 (dd,
J = 6.6, 6.6 Hz, 1H, 1′-H), 7.66 (d, J = 8.2 Hz, 1H, 6-H). 13C NMR (126 MHz, D2O): δ [ppm] = 17.03
(Val-C-4), 18.56 (Val-C-4), 20.71 (Leu-C-4), 22.10 (Leu-C-4), 22.16 (Lys-C-4), 24.46 (Lys-C-5), 25.69 (C-2”),
26.32 (Leu-C-4), 30.02 (Val-C-3), 30.84 (Lys-C-3), 32.95 (C-5′), 35.99 (C-3”), 37.47 (C-2′), 39.29 (Lys-C-6),
39.56 (Leu-C-6), 44.25 (C-1”), 52.65 (Leu-C-2), 54.13 (Lys-C-2), 58.95 (Val-C-2), 59.60 (C-6′), 73.53 (C-3′),
82.56 (C-4′), 86.33 (C-1′), 102.30 (C-5), 142.87 (C-6), 151.51 (C-2), 159.56 (urea-C=O), 166.27 (C-4), 171.90
(C-7′), 174.97 (Leu-C-1), 175.48 (Lys-C-1), 176.79 (Val-C-1). 19F NMR (376 MHz, D2O): δ [ppm] = −75.59
(TFA-CF3). HRMS (ESI+): calcd.: 727.3985 [M + H]+, found: 727.3966. HPLC (semipreparative): tR =
25.9 min (method 1).
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Thymidine-derived muraymycin analogue (15): Nucleosyl amino acid ester 20 (25 mg, 53 µmol)
was dissolved in THF (3 mL), and a solution of aldehyde 17 [42] (42 mg, 68 µmol) in THF (3 mL) was
added. The reaction mixture was stirred over molecular sieve (3 Å) at rt for 24 h. NaBH(OAc)3 (23 mg,
0.11 mmol) and Amberlyst 15TM (3.5 mg, 11 µmol) were added and stirring was continued at rt for 24
h. The reaction mixture was filtered and the residue was washed with EtOAc (150 mL). The combined
filtrates were washed with sat. NaHCO3 solution (100 mL) and brine (50 mL). The aqueous layer
was extracted with EtOAc (3 × 100 mL). The combined organics were dried over Na2SO4 and the
solvent was evaporated under reduced pressure. The resultant crude product was purified by column
chromatography (98:2→95:5, CH2Cl2-MeOH) to give the fully protected muraymycin analogue as a
colorless solid. This was dissolved in aq. TFA (80%, 6.5 mL) and stirred at rt for 24 h. The reaction
mixture was then diluted with water (12 mL) and the solvent was evaporated under reduced pressure.
The resultant crude product was purified by semipreparative HPLC (method 2) to give 15 (bis-TFA
salt) as a colorless foam (9.0 mg, 15% over 2 steps from 20). 1H NMR (500 MHz, D2O): δ [ppm] = 0.83
(d, J = 6.0 Hz, 3H, Leu-5-H), 0.88 (d, J = 5.7 Hz, 3H, Leu-5-H), 0.89 (d, J = 6.6 Hz, 3H, Val-4-H), 0.93 (d,
J = 6.9 Hz, 3H, Val-4-H), 1.31–1.45 (m, 2H, Lys-4-H), 1.50–1.68 (m, 6H, Lys-3-Ha, Lys-5-H, Leu-3-H,
Leu-4-H), 1.73–1.76 (m, 1H, Lys-3-Hb), 1.85–1.90 (m, 2H, 2”-H), 1.86 (s, 3H, 7-H), 2.10–2.16 (m, 1H,
Val-3-H), 2.20–2.25 (m, 1H, 5′-Ha), 2.30 (ddd, J = 14.2, 6.9, 5.0 Hz, 1H, 2′-Ha), 2.39–2.44 (m, 1H, 5′-Hb),
2.46–2.51 (m, 1H, 2′-Hb), 2.96 (t, J = 7.6 Hz, 2H, Lys-6-H), 3.06 (t, J = 7.3 Hz, 2H, 1”-H), 3.20–3.29 (m,
2H, 3”-H), 3.94–3.97 (m, 1H, 6′-H), 4.02 (ddd, J = 10.4, 4.7, 2.8 Hz, 1H, 4′-H), 4.05 (d, J = 5.4 Hz, 1H,
Val-2-H), 4.05–4.10 (dd, J = 8.5, 5.4 Hz, 1H, Lys-2-H), 4.21 (dd, J = 9.8, 4.7 Hz, 1H, Leu-2-H), 4.30–4.33
(m, 1H, 3′-H), 6.16 (dd, J = 6.6, 6.6 Hz, 1H, 1′-H), 7.44 (s, 1H, 6-H). 13C NMR (126 MHz, D2O): δ [ppm]
= 11.57 (C-7), 17.02 (Val-C-4), 18.54 (Val-C-4), 20.70 (Leu-C-4), 22.09 (Leu-C-4), 22.16 (Lys-C-4), 24.45
(Lys-C-5), 25.67 (C-2”), 26.32 (Leu-C-4), 30.00 (Val-C-3), 30.82 (Lys-C-3), 32.73 (C-5′), 35.96 (C-3”), 37.24
(C-2′), 39.28 (Lys-C-6), 39.55 (Leu-C-6), 44.19 (C-1”), 52.62 (Leu-C-2), 54.15 (Lys-C-2), 58.91 (Val-C-2),
59.16 (C-6′), 73.16 (C-3′), 82.30 (C-4′), 85.96 (C-1′), 111.52 (C-5), 116.41 (d, JCF = 291.4 Hz, TFA-CF3),
138.34 (C-6), 151.65 (C-2), 159.56 (urea-C=O), 163.05 (d, JCF = 35.7 Hz, TFA-COO), 166.51 (C-4), 171.57
(C-7′), 174.95 (Leu-C-1), 175.46 (Lys-C-1), 176.73 (Val-C-1). 19F NMR (376 MHz, D2O): δ [ppm] = −75.59
(TFA-CF3). MS (ESI+): m/z = 741.5 [M + H]+, 763.5 [M + Na]+. HRMS (ESI+): calcd.: 741.4141 [M +
H]+, found: 741.4122. HPLC (semipreparative): tR = 13.9 min (method 2).
5,6-Dihydrouridine-derived muraymycin analogue (16): Protected urea dipeptide 46 [24,41]
(15.5 mg, 34.8 µmol) was dissolved in THF (5 mL), and 1-hydroxybenzotriazole (HOBt, 4.9 mg, 36
µmol), benzotriazole-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOB, 18.7 mg, 35.9
µmol) and DIPEA (12.2 µL, 71.8 µmol) were added. The reaction mixture was stirred at rt for 30 min.
After cooling to 0 ◦C, a solution of 5,6-dihydrouridine derivative 45 (25.2 mg, 33.2 µmol) in THF (7
mL) was added. The reaction mixture was stirred at 0 ◦C for 30 min and at rt for 3 h. The solvent
was evaporated under reduced pressure, and the resultant crude product was purified by column
chromatography (98:2→95:5, CH2Cl2-MeOH) to give the fully protected muraymycin analogue. This
was dissolved in aq. TFA (80%, 5 mL) and stirred at rt for 24 h. The reaction mixture was then diluted
with water (15 mL) and the solvent was evaporated under reduced pressure. The resultant crude
product was purified by semipreparative HPLC (method 3) to give 16 (bis-TFA salt) as a colorless
solid (7.9 mg, 32% over 2 steps from 45). 1H NMR (500 MHz, D2O, 15 ◦C): δ [ppm] = 0.79 (d, J = 5.0
Hz, 3H, Leu-5-H), 0.82–0.87 (m, 6H, Leu-5-H, Val-4-H), 0.89 (d, J = 6.4 Hz, 3H, Val-4-H), 1.31–1.41
(m, 2H, Lys-4-H), 1.44–1.56 (m, 3H, Leu-3-H, Leu-4-H), 1.56–1.66 (m, 2H, Lys-5-H), 1.67–1.76 (m, 2H,
Lys-3-H), 1.78–1.89 (m, 2H, 2”-H), 2.04–2.16 (m, 2H, Val-3-H, 5′-Ha), 2.29–2.37 (m, 1H, 5′-Hb), 2.68
(t, J = 6.5 Hz, 2H, 5-H), 2.89–2.94 (m, 2H, Lys-6-H), 2.98–3.04 (m, 2H, 1”-H), 3.16–3.25 (m, 2H, 3”-H),
3.45 (t, J = 6.5 Hz, 2H, 6-H), 3.84–3.88 (m, 1H, 6′-H), 3.89–3.95 (m, 1H, 3′-H), 3.96–4.09 (m, 3H, 4′-H,
Lys-2-H, Val-2-H), 4.12–4.22 (m, 1H, Leu-2-H), 4.25 (dd, J = 5.3, 4.9 Hz, 1H, 2′-H), 5.67 (d, J = 4.9 Hz,
1H, 1′-H). 13C NMR (126 MHz, D2O): δ [ppm] = 17.04 (Val-C-4), 18.56 (Val-C-4), 20.72 (Leu-C-5), 22.10
(Lys-C-4), 22.16 (Leu-C-5), 24.46 (Leu-C-4), 25.69 (C-2”), 26.32 (Lys-C-5), 30.01 (Val-C-3), 30.21 (C-5),
30.83 (Lys-C-3), 33.04 (C-5′), 36.00 (C-3”), 37.56 (C-6), 39.30 (Lys-C-6), 39.60 (Leu-C-3), 44.31 (C-1”),
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52.65 (Leu-C-2), 54.11 (Lys-C-2), 58.95 (Val-C-2), 59.42 (C-6′), 70.50 (C-2′), 73.30 (C-3′), 79.07 (C-4′),
89.51 (C-1′), 116.47 (q, JCF = 291.4 Hz, TFA-CF3), 154.45 (C-2), 159.58 (urea-C=O), 163.10 (q, JCF = 35.6
Hz, TFA-COO), 171.47 (C-7′), 173.75 (C-4), 174.99 (Lys-C-1), 175.46 (Leu-C-1), 176.78 (Val-C-1). 19F
NMR (376 MHz, D2O): δ [ppm] = −76.04 (TFA-CF3). HRMS (ESI+): calcd.: 745.4090 [M + H]+, found:
745.4074. HPLC (semipreparative): tR = 5.9 min (method 3).
(6′S)-5-Fluorouridinyl amino acid tert-butyl ester (18): Cbz-protected nucleosyl amino acid ester
38 (25 mg, 34 µmol) was dissolved in i-PrOH (2 mL). 1,4-Cyclohexadiene (31 µL, 0.34 mmol) and Pd
black (~4 mg, 38 µmol) were added and the reaction mixture was stirred at rt for 3 h. After filtration
through a syringe filter and washing the filter with EtOAc (3 × 5 mL), the solvent of the combined
filtrates was evaporated under reduced pressure to give 18 as a colorless foam (18 mg, 88%). 1H NMR
(500 MHz, CDCl3): δ [ppm] = 0.08 (s, 6H, Si(CH3)2C(CH3)3), 0.12 (s, 6H, Si(CH3)2C(CH3)3), 0.90 (s, 9H,
Si(CH3)2C(CH3)3), 0.91 (s, 9H, Si(CH3)2C(CH3)3), 1.47 (s, 9H, COOC(CH3)3), 1.86 (ddd, J = 17.0, 10.4,
6.3 Hz, 1H, 5′-Ha), 2.18 (ddd, J = 14.2, 6.3, 2.8 Hz, 1H, 5′-Hb), 3.63 (dd, J = 6.3, 6.3 Hz, 1H, 6′-H), 3.67 (dd,
J = 6.6, 4.1 Hz, 1H, 3′-H), 4.16 (dd, J = 4.1, 2.8 Hz, 1H, 2′-H), 4.21 (ddd, J = 10.7, 6.6, 2.9 Hz, 1H, 4′-H),
5.63 (d, J = 1.9 Hz, 1H, 1′-H), 7.58 (d, JHF = 6.0 Hz, 1H, 6-H). 13C NMR (126 MHz, CDCl3): δ [ppm] =
−4.84 (Si(CH3)2C(CH3)3), −4.31 (Si(CH3)2C(CH3)3), 17.91 (Si(CH3)2C(CH3)3), 18.05 (Si(CH3)2C(CH3)3),
25.76 (Si(CH3)2C(CH3)3), 25.84 (Si(CH3)2C(CH3)3), 27.98 (COOC(CH3)3), 37.80 (C-5′), 53.18 (C-6′),
75.01 (C-2′), 75.19 (C-3′), 81.34 (C-4′), 81.74 (COOC(CH3)3), 91.56 (C-1′), 124.26 (d, JCF = 34.8 Hz, C-6),
140.4 (d, JCF = 237.4 Hz, C-5), 148.55 (C-2), 156.82 (d, JCF = 26.6 Hz, C-4). 19F NMR (376 MHz, CDCl3):
−164.54. MS (ESI+): m/z = 604.4 [M + H]+, 626.4 [M + Na]+. HRMS (ESI+): calcd.: 604.3244 [M + H]+,
626.3064 [M + Na]+, found: 604.3232, 626.3051. TLC: Rf = 0.31 (95:5, CH2Cl2-MeOH).
(6′S)-2′-Deoxyuridinyl amino acid tert-butyl ester (19): Cbz-protected nucleosyl amino acid ester
39 (50 mg, 85 µmol) was dissolved in i-PrOH (5 mL). 1,4-Cyclohexadiene (80 µL, 0.85 mmol) and Pd
black (~4 mg, 38 µmol) were added and the reaction mixture was stirred at rt for 1.5 h. After filtration
through a syringe filter and washing the filter with EtOAc (3 × 10 mL), the solvent of the combined
filtrates was evaporated under reduced pressure to give 19 as a colorless foam (38 mg, 98%). 1H NMR
(500 MHz, CDCl3): δ [ppm] = 0.08 (s, 6H, Si(CH3)2C(CH3)3), 0.89 (s, 9H, Si(CH3)2C(CH3)3), 1.47 (s, 9H,
COOC(CH3)3), 1.84 (ddd, J = 14.2, 9.5, 6.9 Hz, 1H, 5′-Ha), 2.11–2.17 (m, 2H, 2′-Ha, 5′-Hb), 2.30 (ddd, J =
13.6, 6.6, 5.4 Hz, 1H, 2′-Hb), 3.57 (dd, J = 6.3, 6.3 Hz, 1H, 6′-H), 3.95 (ddd, J = 9.1, 5.0, 3.5 Hz, 1H, 4′-H),
4.11 (dd, J = 12.0, 5.0 Hz, 1H, 3′-H), 5.76 (d, J = 7.9 Hz, 1H, 5-H), 6.16 (dd, J = 6.0, 6.0 Hz, 1H, 1′-H),
7.44 (d, J = 8.2 Hz, 1H, 6-H). 13C NMR (126 MHz, CDCl3): δ [ppm] = −4.71 (Si(CH3)2C(CH3)3), 17.90
(Si(CH3)2C(CH3)3), 25.66 (Si(CH3)2C(CH3)3), 28.00 (COOC(CH3)3), 37.85 (C-5′), 40.58 (C-2′), 53.09
(C-6′), 74.89 (C-3′), 81.65 (COOC(CH3)3), 84.28 (C-4′), 85.25 (C-1′), 102.55 (C-5), 139.88 (C-6), 149.90
(C-2), 162.86 (C-4), 173.81 (C-7′). MS (ESI+): m/z = 456.1 [M + H]+, 478.2 [M + Na]+. HRMS (ESI+):
calcd.: 456.2524 [M + H]+, found: 456.2498.
(6′S)-Thymidinyl amino acid tert-butyl ester (20): Cbz-protected nucleosyl amino acid ester 40 (50
mg, 83 µmol) was dissolved in i-PrOH (5 mL). 1,4-Cyclohexadiene (77 µL, 0.82 mmol) and Pd black (~4
mg, 38 µmol) were added and the reaction mixture was stirred at rt for 2.5 h. After filtration through
a syringe filter and washing the filter with EtOAc (3 × 10 mL), the solvent of the combined filtrates
was evaporated under reduced pressure to give 20 as a colorless foam (37 mg, 95%). 1H NMR (500
MHz, CDCl3): δ [ppm] = 0.09 (s, 6H, Si(CH3)2C(CH3)3), 0.90 (s, 9H, Si(CH3)2C(CH3)3), 1.47 (s, 9H,
COOC(CH3)3), 1.95 (d, J = 1.1 Hz, 3H, 7-H), 1.86 (ddd, J = 16.1, 9.3, 6.9 Hz, 1H, 5′-Ha), 2.13–2.18 (m,
2H, 2′-Ha, 5′-Hb), 2.26 (ddd, J = 13.6, 6.7, 5.0 Hz, 1H, 2′-Hb), 3.58 (dd, J = 6.4, 6.4 Hz, 1H, 6′-H), 3.93
(ddd, J = 9.2, 4.9, 4.0 Hz, 1H, 4′-H), 4.13 (dd, J = 12.1, 5.0 Hz, 1H, 3′-H), 6.17 (dd, J = 6.5, 6.5 Hz, 1H,
1′-H), 7.20 (d, J = 1.1 Hz, 1H, 6-H). 13C NMR (126 MHz, CDCl3): δ [ppm] = −4.71 (Si(CH3)2C(CH3)3),
12.58 (C-7), 17.90 (Si(CH3)2C(CH3)3), 25.67 (Si(CH3)2C(CH3)3), 27.98 (COOC(CH3)3), 37.86 (C-5′), 40.33
(C-2′), 53.10 (C-6′), 75.00 (C-3′), 81.57 (COOC(CH3)3), 84.04 (C-4′), 84.87 (C-1′), 111.07 (C-5), 135.63
(C-6), 149.97 (C-2), 163.43 (C-4), 173.88 (C-7′). MS (ESI+): m/z = 470.1 [M + H]+, 492.3 [M + Na]+.
HRMS (ESI+): calcd.: 470.2681 [M + H]+, found: 470.2658.
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2′,3′,5′-Tris-O-TBDMS-5-fluorouridine (24): 5-Fluorouridine 21 (2.00 g, 7.62 mmol) was coevaporated
with dry pyridine (2 × 14 mL). Pyridine (26 mL), imidazole (1.56 g, 22.8 mmol) and TBDMSCl (5.74
g, 38.1 mmol) were added and the reaction mixture was stirred at rt for 4 d. Water (90 mL) was then
added at 0 ◦C. The solvent was evaporated under reduced pressure, the resultant colorless residue
was dissolved in EtOAc (100 mL) and washed with sat. NaHCO3 solution (3 × 100 mL) and brine (2
× 20 mL). The organic layer was dried over Na2SO4 and the solvent was evaporated under reduced
pressure. The resultant crude product was purified by column chromatography (7:3, petroleum
ether-EtOAc) to give 24 as a colorless foam (2.87 g, 62%). 1H NMR (500 MHz, CDCl3): δ [ppm] = 0.07
(s, 6H, Si(CH3)2C(CH3)3), 0.09 (s, 6H, Si(CH3)2C(CH3)3), 0.16 (s, 6H, Si(CH3)2C(CH3)3), 0.89 (s, 9H,
Si(CH3)2C(CH3)3), 0.92 (s, 9H, Si(CH3)2C(CH3)3), 0.97 (s, 9H, Si(CH3)2C(CH3)3), 3.77 (dd, J = 11.7,
1.0 Hz, 1H, 5′-Ha), 4.01 (dd, J = 11.7, 1.2 Hz, 1H, 5′-Hb), 4.06–4.10 (m, 3H, 2′-H, 3′-H, 4′-H), 5.89 (dd,
J = 4.1, 1.2 Hz, 1H, 1′-H), 8.18 (d, JHF = 6.3 Hz, 1H, 6-H), 8.73 (bs, 1H, 3-NH). 13C NMR (126 MHz,
CDCl3): δ [ppm] = −5.54 (Si(CH3)2C(CH3)3), −4.81 (Si(CH3)2C(CH3)3), −3.94 (Si(CH3)2C(CH3)3), 17.92
(Si(CH3)2C(CH3)3), 18.05 (Si(CH3)2C(CH3)3), 18.61 (Si(CH3)2C(CH3)3), 25.70 (Si(CH3)2C(CH3)3), 25.79
(Si(CH3)2C(CH3)3), 26.06 (Si(CH3)2C(CH3)3), 62.15 (C-5′), 71.16 (C-3′), 76.12 (C-4′), 85.11 (C-2′), 88.78
(C-1′), 124.41 (d, JCF = 33.9 Hz, C-6), 140.37 (d, JCF = 236.4 Hz, C-5), 148.65 (C-2), 156.67 (d, JCF = 26.6
Hz, C-4). 19F NMR (376 MHz, CDCl3): δ [ppm] = −164.60. MS (ESI−): m/z = 605.3 [M + H]+, 627.3
[M + Na]+. HRMS (ESI)+: calcd.: 605.3268 [M + H]+, found: 605.3261. TLC: Rf = 0.85 (1:1, petroleum
ether-EtOAc).
3′,5′-Bis-O-TBDMS-2′-deoxyuridine (25): 2′-Deoxyuridine 22 (5.09 g, 22.3 mmol) was coevaporated
with dry pyridine (2 × 40 mL). Pyridine (75 mL), imidazole (4.58 g, 66.9 mmol) and TBDMSCl (10.1 g,
66.9 mmol) were added and the reaction mixture was stirred at rt for 31 h. Water (50 mL) was then
added at 0 ◦C. The solvent was evaporated under reduced pressure, the resultant colorless residue
was dissolved in EtOAc (250 mL) and washed with sat. NaHCO3 solution (3 × 125 mL) and brine
(50 mL). The organic layer was dried over Na2SO4 and the solvent was evaporated under reduced
pressure. The resultant crude product was purified by column chromatography (3:2, petroleum
ether-EtOAc) to give 25 as a colorless solid (9.90 g, 97%). 1H NMR (300 MHz, CDCl3): δ [ppm] = 0.08
(s, 3H, Si(CH3)2C(CH3)3), 0.09 (s, 3H, Si(CH3)2C(CH3)3), 0.11 (s, 3H, Si(CH3)2C(CH3)3), 0.11 (s, 3H,
Si(CH3)2C(CH3)3), 0.90 (s, 9H, Si(CH3)2C(CH3)3), 0.98 (s, 9H, Si(CH3)2C(CH3)3), 2.07 (ddd, J = 13.2,
6.2, 6.2 Hz, 1H, 2′-Ha), 2.33 (ddd, J = 13.2, 6.2, 4.2 Hz, 1H, 2′-Hb), 3.77 (dd, J = 11.3, 2.5 Hz, 1H, 5′-Ha),
3.90 (dd, J = 11.3, 2.5 Hz, 1H, 5′-Hb), 3.92–3.94 (m, 1H, 4′-H), 4.42 (ddd, J = 6.0, 6.0, 3.8 Hz, 1H, 3′-H),
5.68 (d, J = 8.0 Hz, 1H, 5-H), 6.29 (dd, J = 6.2, 6.2 Hz, 1H, 1′-H), 7.47 (d, J = 8.0 Hz, 1H, 6-H), 8.16 (s, 1H,
3-NH). 13C NMR (126 MHz, CDCl3): δ [ppm] = −5.43 (Si(CH3)2C(CH3)3), −5.36 (Si(CH3)2C(CH3)3),
−4.72 (Si(CH3)2C(CH3)3), −4.47 (Si(CH3)2C(CH3)3), 18.12 (Si(CH3)2C(CH3)3), 18.50 (Si(CH3)2C(CH3)3),
25.86 (Si(CH3)2C(CH3)3), 26.02 (Si(CH3)2C(CH3)3), 42.00 (C-2′), 62.60 (C-5′), 71.38 (C-3′), 85.35 (C-1′),
87.94 (C-4′), 102.25 (C-5), 140.34 (C-6), 150.10 (C-2), 162.95 (C-4). HRMS (CI): calcd.: 457.2549 [M + H]+,
found: 457.2538. TLC: Rf = 0.40 (1:1, CH2Cl2-EtOAc).
3′,5′-Bis-O-TBDMS-thymidine (26): Thymidine 23 (5.40 g, 22.3 mmol) was coevaporated with
dry pyridine (2 × 22 mL). Pyridine (50 mL), imidazole (3.88 g, 57.0 mmol) and TBDMSCl (8.43 g,
56.0 mmol) were added and the reaction mixture was stirred at rt for 48 h. Water (50 mL) was then
added at 0 ◦C. The solvent was evaporated under reduced pressure, the resultant colorless residue
was dissolved in EtOAc (250 mL) and washed with sat. NaHCO3 solution (3 × 125 mL) and brine
(50 mL). The organic layer was dried over Na2SO4 and the solvent was evaporated under reduced
pressure. The resultant crude product was purified by column chromatography (3:1, petroleum
ether-EtOAc) to give 26 as a colorless solid (9.81 g, 94%). 1H NMR (300 MHz, CDCl3): δ [ppm] =
0.08 (s, 3H, Si(CH3)2C(CH3)3), 0.08 (s, 3H, Si(CH3)2C(CH3)3), 0.11 (s, 3H, Si(CH3)2C(CH3)3), 0.11
(s, 3H, Si(CH3)2C(CH3)3), 0.90 (s, 9H, Si(CH3)2C(CH3)3), 0.93 (s, 9H, Si(CH3)2C(CH3)3), 1.92 (d, J =
0.8 Hz, 3H, 7-H), 1.95–2.05 (m, 1H, 2′-Ha), 2.25 (ddd, J = 13.1, 5.8, 2.5 Hz, 1H, 2′-Hb) 3.76 (dd, J =
11.4, 2.5 Hz, 1H, 5′-Ha), 3.87 (dd, J = 11.4, 2.5 Hz, 1H, 5′-Hb), 3.94 (dd, J = 2.5, 2.5 Hz, 1H, 4′-H),
4.41 (ddd, J = 5.8, 2.5, 2.5 Hz, 1H, 3′-H), 6.33 (dd, J = 8.0, 5.8 Hz, 1H, 1′-H), 7.47 (d, J = 0.8 Hz,
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1H, 6-H), 8.03 (s, 1H, 3-NH). 13C NMR (126 MHz, CDCl3): δ [ppm] = −5.29 (Si(CH3)2C(CH3)3),
−5.20 (Si(CH3)2C(CH3)3), −4.67 (Si(CH3)2C(CH3)3), −4.48 (Si(CH3)2C(CH3)3), 12.68 (C-7), 18.17
(Si(CH3)2C(CH3)3), 18.57 (Si(CH3)2C(CH3)3), 25.90 (Si(CH3)2C(CH3)3), 26.09 (Si(CH3)2C(CH3)3), 41.53
(C-2′), 63.16 (C-5′), 72.45 (C-3′), 85.00 (C-1′), 88.01 (C-4′), 110.93 (C-5), 135.64 (C-6), 150.17 (C-2), 163.52
(C-4). HRMS (CI): calcd.: 471.2705 [M + H]+, found: 471.2694. TLC: Rf = 0.29 (1:1, CH2Cl2-EtOAc).
2′,3′-Bis-O-TBDMS-5-fluorouridine (27): 2′,3′,5′-Tris-O-TBDMS-5-fluorouridine 24 (1.09 g, 1.80
mmol) was dissolved in THF (22 mL) and aq. TFA (50%, 5.4 mL) was added slowly at 0 ◦C over 40 min.
The reaction mixture was stirred at 0 ◦C for 5.5 h. After conversion was sufficient according to TLC, sat.
NaHCO3 solution (70 mL) was added until pH 8 was reached. The aqueous layer was extracted with
EtOAc (3 × 70 mL) and the combined organics were dried over Na2SO4. The solvent was evaporated
under reduced pressure, and the resultant crude product was purified by column chromatography
(7:3, petroleum ether-EtOAc) to give 27 as a colorless foam (610 mg, 69%). 1H NMR (500 MHz, CDCl3):
δ [ppm] = 0.09 (s, 6H, Si(CH3)2C(CH3)3), 0.10 (s, 6H, Si(CH3)2C(CH3)3), 0.90 (s, 9H, Si(CH3)2C(CH3)3),
0.92 (s, 9H, Si(CH3)2C(CH3)3), 2.45 (bs, 1H, 5′-OH), 3.80 (ddd, J = 11.9, 5.0, 1.9 Hz, 1H, 5′-Ha), 4.04
(ddd, J = 11.6, 2.2 Hz, 1H, 5′-Hb), 4.11 (d, J = 5.0 Hz, 1H, 4′-H), 4.16 (dd, J = 4.7, 4.4 Hz, 1H, 3′-H), 4.34
(dd, J = 4.7, 4.4 Hz, 1H, 2′-H), 5.60 (d, J = 6.0 Hz, 1H, 1′-H), 8.12 (d, JHF = 6.6 Hz, 1H, 6-H), 9.00 (bs, 1H,
3-NH). 13C NMR (126 MHz, CDCl3): δ [ppm] = −4.84 (Si(CH3)2C(CH3)3), −4.55 (Si(CH3)2C(CH3)3),
17.95 (Si(CH3)2C(CH3)3), 18.05 (Si(CH3)2C(CH3)3), 25.75 (Si(CH3)2C(CH3)3), 25.80 (Si(CH3)2C(CH3)3),
60.89 (C-5′), 70.76 (C-4′), 74.87 (C-2′), 84.88 (C-3′), 91.89 (C-1′), 126.12 (d, JCF = 34.8 Hz, C-6), 139.29 (d,
JCF = 236.4 Hz, C-5), 148.76 (C-2), 156.78 (d, JCF = 26.6 Hz, C-4). 19F NMR (376 MHz, CDCl3): δ [ppm]
= −165.47. MS (ESI+): m/z = 513.2 [M + Na]+. HRMS (ESI+): calcd.: 491.2403 [M + H]+, 513.2223 [M +
Na]+, found: 491.2392, 513.2210. TLC: Rf = 0.19 (7:3, petroleum ether-EtOAc).
3′-O-TBDMS-2′-deoxyuridine (28): 3′,5′-Bis-O-TBDMS-2′-deoxyuridine 25 (7.09 g, 15.5 mmol)
was dissolved in MeOH (200 mL) and cooled to −10 ◦C. Acetyl chloride (273 µL, 3.84 mmol) was added
slowly at this temperature. The mixture was warmed to 0 ◦C and stirred at this temperature for 2.5 h.
After conversion was sufficient according to TLC, sat. NaHCO3 solution (150 mL) was added and the
mixture was stirred for 15 min. Then EtOAc (300 mL), water (100 mL) and brine (200 mL) were added.
The organic layer was washed with sat. NaHCO3 solution (100 mL), brine (2 x 100 mL) and water (100
mL) and dried over Na2SO4. The solvent was evaporated under reduced pressure, and the resultant
crude product was purified by column chromatography (3:2, petroleum ether-EtOAc→7:3, petroleum
ether-EtOAc→EtOAc) to give 28 as a colorless solid (3.47 g, 65%). 1H NMR (500 MHz, CDCl3): δ [ppm]
= 0.08 (s, 6H, Si(CH3)2C(CH3)3), 0.89 (s, 9H, Si(CH3)2C(CH3)3), 2.26–2.30 (m, 2H, 2′-H), 2.51 (dd, J =
4.6, 4.6 Hz, 1H, 5′-OH), 3.76 (ddd, J = 11.6, 5.8, 3.2 Hz, 1H, 5′-Ha), 3.89–3.91 (m, 1H, 5′-Hb), 3.92–3.94
(m, 1H, 4′-H), 4.48 (ddd, J = 5.9, 4.2, 4.2 Hz, 1H, 3′-H), 5.73 (d, J = 8.1 Hz, 1H, 5-H), 6.18 (dd, J = 6.6, 6.6
Hz, 1H, 1′-H), 7.68 (d, J = 8.1 Hz, 1H, 6-H), 9.33 (s, 1H, 3-NH). 13C NMR (126 MHz, CDCl3): δ [ppm] =
−4.90 (Si(CH3)2C(CH3)3), −4.74 (Si(CH3)2C(CH3)3), 17.92 (Si(CH3)2C(CH3)3), 25.67 (Si(CH3)2C(CH3)3),
40.87 (C-2′), 61.73 (C-5′), 71.38 (C-3′), 86.60 (C-1′), 87.61 (C-4′), 102.40 (C-5), 141.15 (C-6), 150.30 (C-2),
163.56 (C-4). HRMS (CI): calcd.: 343.1684 [M + H]+, found: 343.1687. TLC: Rf = 0.44 (EtOAc).
3′-O-TBDMS-thymidine (29): 3′,5′-Bis-O-TBDMS-thymidine 26 (7.02 g, 14.9 mmol) was dissolved
in MeOH (340 mL) and cooled to −10 ◦C. Acetyl chloride (265 µL, 3.73 mmol) was added slowly at
this temperature. The mixture was warmed to 0 ◦C and stirred at this temperature for 3.5 h. After
conversion was sufficient according to TLC, sat. NaHCO3 solution (150 mL) was added and the
mixture was stirred for 15 min. Then EtOAc (300 mL), water (100 mL) and brine (400 mL) were added.
The organic layer was washed with sat. NaHCO3 solution (2 × 100 mL), water (100 mL) and brine (100
mL) and dried over Na2SO4. The solvent was evaporated under reduced pressure, and the resultant
crude product was purified by column chromatography (1:1, petroleum ether-EtOAc) to give 29 as a
colorless solid (3.21 g, 59%). 1H NMR (500 MHz, CDCl3): δ [ppm] = 0.09 (s, 6H, Si(CH3)2C(CH3)3),
0.90 (s, 9H, Si(CH3)2C(CH3)3), 1.92 (d, J = 1.1 Hz, 3H, 7-H), 2.22 (ddd, J = 13.3, 6.4, 3.8 Hz, 1H, 2′-Ha),
2.33–2.42 (m, 1H, 2′-Hb), 2.60 (brs, 1H, 5′-OH), 3.76 (ddd, J = 12.4, 6.5, 3.5 Hz, 1H, 5′-Ha), 3.90–3.95
(m, 2H, 4′-H, 5′-Hb), 4.48–4.52 (m, 1H, 3′-H), 6.14 (dd, J = 6.8, 6.8 Hz, 1H, 1′-H), 7.36 (d, J = 1.1 Hz,
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1H, 6-H), 8.63 (s, 1H, 3-NH). 13C NMR (126 MHz, CDCl3): δ [ppm] = −4.87 (Si(CH3)2C(CH3)3), −4.71
(Si(CH3)2C(CH3)3), 12.52 (C-7), 17.94 (Si(CH3)2C(CH3)3), 25.70 (Si(CH3)2C(CH3)3), 40.41 (C-2′), 62.05
(C-5′), 71.60 (C-3′), 87.09 (C-1′), 87.56 (C-4′), 111.00 (C-5), 137.05 (C-6), 150.24 (C-2), 163.59 (C-4). HRMS
(CI): calcd.: 357.1840 [M + H]+, found: 357.1848. TLC: Rf = 0.35 (1:1, petroleum ether-EtOAc).
2′,3′-Bis-O-TBDMS-5-fluorouridine-5′-aldehyde (30): 2′,3′-Bis-O-TBDMS-5-fluorouridine 27 (992
mg, 2.02 mmol) was dissolved in MeCN (21 mL) and IBX (1.19 g, 4.26 mmol) was added. The reaction
mixture was stirred under reflux for 1.5 h. After cooling to 0 ◦C, stirring was continued for 30 min.
The reaction mixture was then filtered and the solid residue was washed with EtOAc (6 × 40 mL).
The solvent of the combined filtrates was evaporated under reduced pressure to give 30 as a colorless
foam (910 mg, 92%). This material was used in the following step without further purification and
characterization with respect to its limited stability. 1H NMR (500 MHz, CDCl3): δ [ppm] = 0.04
(s, 6H, Si(CH3)2C(CH3)3), 0.14 (s, 6H, Si(CH3)2C(CH3)3), 0.89 (s, 9H, Si(CH3)2C(CH3)3), 0.94 (s, 9H,
Si(CH3)2C(CH3)3), 4.18 (dd, J = 5.4, 4.1 Hz, 1H, 4′-H), 4.21 (dd, J = 4.1, 4.1 Hz, 1H, 3′-H), 4.64 (d, J = 3.5
Hz, 1H, 2′-H), 5.82 (dd, J = 5.4, 1.0 Hz, 1H, 1′-H), 8.02 (d, JHF = 6.0 Hz, 1H, 6-H), 8.53 (brs, 1H, 3-NH),
9.83 (s, 1H, 5’-H).
3′-O-TBDMS-2′-deoxyuridine-5′-aldehyde (31): 3′-O-TBDMS-2′-deoxyuridine 28 (1.25 g, 3.66
mmol) was dissolved in MeCN (35 mL) and IBX (2.56 g, 9.15 mmol) was added. The reaction mixture
was stirred under reflux for 2 h. After cooling to 0 ◦C, stirring was continued for 30 min. The reaction
mixture was then filtered and the solid residue was washed with EtOAc (3 × 50 mL). The solvent of the
combined filtrates was evaporated under reduced pressure to give 31 as a colorless foam (1.25 g, quant.).
This material was used in the following step without further purification and characterization with
respect to its limited stability. 1H NMR (500 MHz, CDCl3): δ [ppm] = 0.13 (s, 3H, Si(CH3)2C(CH3)3),
0.14 (s, 3H, Si(CH3)2C(CH3)3), 0.91 (s, 9H, Si(CH3)2C(CH3)3), 1.97–2.03 (m, 1H, 2′-Ha), 2.37 (ddd, J =
13.6, 5.8, 2.2 Hz, 1H, 2′-Hb), 4.52 (d, J = 2.0 Hz, 1H, 4′-H), 4.64–4.68 (m, 1H, 3′-H), 5.81 (d, J = 8.2 Hz,
1H, 5-H), 6.31 (dd, J = 8.1, 5.8 Hz, 1H, 1′-H), 7.85 (d, J = 8.2 Hz, 1H, 6-H), 9.26 (brs, 1H, 3-NH), 9.75 (s,
1H, 5′-H).
3′-O-TBDMS-thymidine-5′-aldehyde (32): 3′-O-TBDMS-thymidine 29 (1.32 g, 3.70 mmol) was
dissolved in MeCN (35 mL) and IBX (2.59 g, 9.25 mmol) was added. The reaction mixture was stirred
under reflux for 1 h. After cooling to 0 ◦C, stirring was continued for 30 min. The reaction mixture was
then filtered and the solid residue was washed with EtOAc (3 × 40 mL). The solvent of the combined
filtrates was evaporated under reduced pressure to give 32 as a colorless foam (1.31 g, quant.). This
material was used in the following step without further purification and characterization with respect
to its limited stability. 1H NMR (500 MHz, CDCl3): δ [ppm] = 0.15 (s, 3H, Si(CH3)2C(CH3)3), 0.16 (s,
3H, Si(CH3)2C(CH3)3), 0.94 (s, 9H, Si(CH3)2C(CH3)3), 1.98 (d, J = 1.1 Hz, 3H, 7-H), 2.03–2.12 (m, 1H,
2′-Ha), 2.34 (ddd, J = 13.4, 5.9, 1.9 Hz, 1H, 2′-Hb), 4.50 (d, J = 2.1 Hz, 1H, 4′-H), 4.69 (ddd, J = 5.2, 2.1,
1.9 Hz, 1H, 3′-H), 6.33 (dd, J = 8.1, 5.9 Hz, 1H, 1′-H), 7.59 (d, J = 1.1 Hz, 1H, 6-H), 8.76 (brs, 1H, 3-NH),
9.78 (s, 1H, 5′-H).
Z-6′-N-Cbz-5′,6′-didehydro-5-fluorouridinyl amino acid tert-butyl ester (34): THF (8 mL) was
added to a solution of KHMDS in toluene (0.5 M, 2.84 mL, 1.42 mmol). After cooling to –86 ◦C,
a solution of phosphonate 33 [31] (480 mg, 1.42 mmol) in THF (10 mL) was added slowly at this
temperature. The mixture was stirred at –86 ◦C for 30 min. Subsequently, a solution of aldehyde 30 (900
mg, 1.85 mmol) in THF (12 mL) was added dropwise. Stirring was continued for 16 h while the solution
was allowed to slowly warm to rt. After cooling to 10 ◦C, MeOH (3.2 mL) was added. The mixture
was diluted with EtOAc (70 mL) and washed with half-sat. NaCl solution (2 × 65 mL). The organic
layer was dried over Na2SO4 and the solvent was evaporated under reduced pressure. The resultant
crude product was purified by threefold column chromatography (7:3, petroleum ether-EtOAc and 3:1,
petroleum ether-EtOAc, respectively) to give 34 (9:1 mixture of Z and E isomers as determined by 1H
NMR spectroscopy) as a colorless foam (184 mg, 14%). Z-34: 1H NMR (500 MHz, CDCl3): δ [ppm]
= 0.07 (s, 6H, Si(CH3)2C(CH3)3), 0.12 (s, 6H, Si(CH3)2C(CH3)3), 0.90 (s, 9H, Si(CH3)2C(CH3)3), 0.91
(s, 9H, Si(CH3)2C(CH3)3), 1.49 (s, 9H, COOC(CH3)3), 3.90 (dd, J = 3.8, 3.8 Hz, 1H, 3′-H), 4.28 (dd, J =
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3.5, 3.5 Hz, 1H, 2′-H), 4.92 (dd, J = 7.0, 7.0 Hz, 1H, 4′-H), 5.13–5.18 (m, 2H, 1”-H), 5.60 (d, J = 2.9 Hz,
1H, 1′-H), 6.24 (d, J = 7.8 Hz, 1H, 5′-H), 6.80 (brs, 1H, 6′-NH), 7.34–7.36 (m, 5H, aryl-H), 7.39 (d, JHF
= 6.0 Hz, 1H, 6-H), 8.48 (d, JHF = 4.4 Hz, 1H, 3-NH). 13C NMR (126 MHz, CDCl3): δ [ppm] = −4.81
(Si(CH3)2C(CH3)3), −4.47 (Si(CH3)2C(CH3)3), 18.02 (Si(CH3)2C(CH3)3), 18.10 (Si(CH3)2C(CH3)3), 25.75
(Si(CH3)2C(CH3)3), 25.82 (Si(CH3)2C(CH3)3), 27.84 (COOC(CH3)3), 67.60 (C-1”), 74.90 (C-2′), 76.03
(C-3′), 79.44 (C-4′), 82.90 (COOC(CH3)3), 92.21 (C-1′), 124.28 (C-5′), 124.55 (d, JCF = 34.8 Hz, C-6),
128.20 (C-3”/C-4”), 128.52 (C-3”/C-4”), 131.28 (C-2”), 135.71 (C-5”), 140.26 (d, JCF = 238.3 Hz, C-5),
148.09 (C-2), 156.19 (d, JCF = 27.5 Hz, C-4). 19F NMR (376 MHz, CDCl3): δ [ppm] = −164.45. MS
(ESI+): m/z = 736.4 [M + H]+, 758.5 [M + Na]+. HRMS (ESI+): calcd.: 736.3455 [M + H]+, 758.3275 [M +
Na]+, found: 736.3433, 758.3256. TLC: Rf = 0.60 (1:1, petroleum ether-EtOAc). E-29: 1H NMR (500
MHz, CDCl3): δ [ppm] = 0.07 (s, 6H, Si(CH3)2C(CH3)3), 0.12 (s, 6H, Si(CH3)2C(CH3)3), 0.90 (s, 9H,
Si(CH3)2C(CH3)3), 0.91 (s, 9H, Si(CH3)2C(CH3)3), 1.49 (s, 9H, COOC(CH3)3), 3.84 (dd, J = 5.7, 4.1 Hz,
1H, 3′-H), 4.23 (dd, J = 3.8, 3.5 Hz, 1H, 2′-H), 5.16 (d, J = 1.3 Hz, 2H, 1”-H), 5.46 (dd, J = 9.8, 6.0 Hz, 1H,
4′-H), 5.68 (d, J = 4.1 Hz, 1H, 1′-H), 6.86 (d, J = 9.5 Hz, 1H, 5′-H), 7.26–7.38 (m, 5H, aryl-H), 7.55 (d, JHF
= 6.3 Hz, 1H, 6-H). 19F NMR (376 MHz, CDCl3): δ [ppm] = −164.09. MS (ESI+): m/z = 736.4 [M + H]+,
758.5 [M + Na]+. TLC: Rf = 0.66 (1:1, petroleum ether-EtOAc).
Z-6′-N-Cbz-5′,6′-didehydro-2′-deoxyuridinyl amino acid tert-butyl ester (35): KOt-Bu (460 mg,
4.06 mmol) was dissolved in THF (15 mL). After cooling to −87 ◦C, a solution of phosphonate 33 [31]
(1.50 g, 4.02 mmol) in THF (30 mL) was added slowly at this temperature. The mixture was stirred at
−86 ◦C for 30 min. Subsequently, a solution of aldehyde 31 (1.25 g, 3.66 mmol) in THF (12 mL) was
added dropwise. Stirring was continued for 18.5 h while the solution was allowed to slowly warm to rt.
After cooling to 0 ◦C, MeOH (5 mL) was added and the mixture was stirred for further 40 min. It was
then diluted with EtOAc (150 mL) and washed with half-sat. NaCl solution (3 × 100 mL). The organic
layer was dried over Na2SO4 and the solvent was evaporated under reduced pressure. The resultant
crude product was purified by column chromatography (1:1, petroleum ether-EtOAc) to give 35 as a
colorless foam (1.54 g, 72%). 1H NMR (500 MHz, CDCl3): δ [ppm] = 0.08 (s, 3H, Si(CH3)2C(CH3)3),
0.09 (s, 3H, Si(CH3)2C(CH3)3), 0.88 (s, 9H, Si(CH3)2C(CH3)3), 1.47 (s, 9H, COOC(CH3)3), 2.16 (ddd, J
= 13.6, 6.2, 6.2 Hz, 1H, 2′-Ha), 2.41 (ddd, J = 13.6, 6.2, 4.7 Hz, 1H, 2′-Hb), 4.33 (ddd, J = 6.2, 4.7, 4.6
Hz, 1H, 3′-H), 4.71 (dd, J = 7.8, 4.6 Hz, 1H, 4′-H), 5.14 (d, J = 4.0 Hz, 2H, 1”-H), 5.73 (dd, J = 8.1, 2.2
Hz, 1H, 5-H), 6.13 (d, J = 7.8 Hz, 1H, 5′-H), 6.14 (dd, J = 6.2, 6.2 Hz, 1H, 1′-H), 6.78 (s, 1H, 6′-NH),
7.29-7.40 (m, 6H, aryl-H, 6-H), 8.75 (brs, 1H, 3-NH). 13C NMR (126 MHz, CDCl3): δ [ppm] = −4.76
(Si(CH3)2C(CH3)3), −4.64 (Si(CH3)2C(CH3)3), 18.06 (Si(CH3)2C(CH3)3), 25.81 (Si(CH3)2C(CH3)3), 28.03
(COOC(CH3)3), 40.88 (C-2′), 67.75 (C-1”), 75.97 (C-3′), 82.85 (C-4′), 82.92 (COOC(CH3)3), 86.69 (C-1′),
102.60 (C-5), 124.91 (C-5′), 128.40 (C-3”,C-7”), 128.51 (C-5”), 128.68 (C-4”, C-6”), 130.36 (C-6′), 135.85
(C-2”), 139.78 (C-6), 149.98 (C-2), 153.70 (Cbz-C=O), 162.83 (C-4), 171.13 (C-7′). HRMS (CI): calcd.:
588.2736 [M + H]+, found: 588.2717. TLC: Rf = 0.26 (EtOAc).
Z-6′-N-Cbz-5′,6′-didehydro-thymidinyl amino acid tert-butyl ester (36): KOt-Bu (466 mg,
4.06 mmol) was dissolved in THF (35 mL). After cooling to −80 ◦C, a solution of phosphonate
33 [31] (1.52 g, 4.06 mmol) in THF (30 mL) was added slowly at this temperature. The mixture was
stirred at –86 ◦C for 30 min. Subsequently, a solution of aldehyde 32 (1.31 g, 3.70 mmol) in THF (12
mL) was added dropwise. Stirring was continued for 21 h while the solution was allowed to slowly
warm to rt. After cooling to 0 ◦C, MeOH (5 mL) was added. The mixture was diluted with EtOAc (150
mL) and washed with half-sat. NaCl solution (3 × 100 mL). The organic layer was dried over Na2SO4
and the solvent was removed under reduced pressure. The resultant crude product was purified by
twofold column chromatography (3:2, petroleum ether-EtOAc) to give 36 (95:5 mixture of Z and E
isomers as determined by 1H NMR spectroscopy) as a colorless foam (1.71 g, 77%). 1H NMR (300
MHz, CDCl3): δ [ppm] = 0.09 (s, 3H, Si(CH3)2C(CH3)3), 0.09 (s, 3H, Si(CH3)2C(CH3)3), 0.89 (s, 9H,
Si(CH3)2C(CH3)3), 1.47 (s, 9H, COOC(CH3)3), 1.92 (s, 3H, 7-H), 2.16 (ddd, J = 13.5, 6.2, 6.2 Hz, 1H,
2′-Ha), 2.36 (ddd, J = 13.5, 6.2, 4.7 Hz, 1H, 2′-Hb), 4.35 (ddd, J = 6.2, 4.7, 4.6 Hz, 1H, 3′-H), 4.70 (dd, J =
7.8, 4.6 Hz, 1H, 4′-H), 5.14 (d, J = 4.0 Hz, 2H, 1”-H), 6.13 (d, J = 7.8 Hz, 1 H, 5′-H), 6.14 (dd, J = 6.2, 6.2
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Hz, 1H, 1′-H), 6.81 (s, 1H, 6′-NH), 7.13 (s, 1H, 6-H), 7.29–7.40 (m, 5H, aryl-H), 8.71 (s, 1H, 3-NH). 13C
NMR (126 MHz, CDCl3): δ [ppm] = −4.76 (Si(CH3)2C(CH3)3), −4.64 (Si(CH3)2C(CH3)3), 12.78 (C-7),
18.05 (Si(CH3)2C(CH3)3), 25.81 (Si(CH3)2C(CH3)3), 28.02 (COOC(CH3)3), 40.57 (C-2′), 67.73 (C-1”),
76.13 (C-3′), 82.85 (COOC(CH3)3), 83.34 (C-4′), 86.39 (C-1′), 111.20 (C-5), 124.95 (C-5′), 128.38 (C-3”,
C-7”), 128.49 (C-5”), 128.68 (C-4”, C-6”), 130.67 (C-6′), 135.61 (C-6), 135.86 (C-2”), 150.12 (C-2), 153.71
(Cbz-C=O), 162.91 (C-4), 163.67 (C-7′). HRMS (CI): calcd.: 602.2892 [M + H]+, found: 602.2888. TLC:
Rf = 0.31 (55:45, petroleum ether-EtOAc).
(6′S)-6′-N-Cbz-5-fluorouridinyl amino acid tert-butyl ester (38): Under strict exclusion of oxygen,
didehydro amino acid 34 (9:1 mixture of Z and E isomers, 280 mg, 0.381 mmol) was dissolved in
MeOH (13 mL). After addition of (S,S)-Me-DUPHOS-Rh 37 (~8 mg, 12 µmol), the solution was stirred
under an H2 atmosphere (~1 bar) at rt for 6 d. The reaction was monitored by 1H NMR spectroscopy.
Additional catalyst 37 (~4 mg, 6 µmol) was added after further 5 d and 2 d, respectively, until the
conversion of starting material 34 was complete. The solvent was evaporated under reduced pressure,
and the resultant crude product was purified by threefold column chromatography (3:1, petroleum
ether-EtOAc and 9:1, petroleum ether-EtOAc and CH2Cl2→95:5, CH2Cl2-EtOAc, respectively) to give 38
as a colorless foam (133 mg, 51%). 1H NMR (500 MHz, CDCl3): δ [ppm] = 0.07 (s, 6H, Si(CH3)2C(CH3)3),
0.12 (s, 6H, Si(CH3)2C(CH3)3), 0.89 (s, 9H, Si(CH3)2C(CH3)3), 0.91 (s, 9H, Si(CH3)2C(CH3)3), 1.46 (s,
9H, COOC(CH3)3), 2.02 (ddd, J = 14.2, 8.2, 3.8 Hz, 1H, 5′-Ha), 2.19 (ddd, J = 14.2, 8.2, 2.2 Hz, 1H, 5′-Hb),
3.63 (dd, J = 6.0, 4.1 Hz, 1H, 3′-H), 4.14 (dd, J = 4.1, 3.2 Hz, 1H, 2′-H), 4.25 (ddd, J = 10.8, 6.3, 1.9 Hz,
1H, 4′-H), 4.45 (ddd, J = 7.6, 7.6, 3.8 Hz, 1H, 6′-H), 5.12 (s, 2H, 1”-H), 5.61 (d, J = 6.9 Hz, 1H, 6′-NH),
5.62 (d, 3J = 1.9 Hz, 1H, 1′-H), 7.31–7.38 (m, 5H, aryl-H), 7.84 (d, JHF = 6.0 Hz, 1H, 6-H), 8.95 (brs, 1H,
3-NH). 13C NMR (126 MHz, CDCl3): δ [ppm] = −4.85 (Si(CH3)2C(CH3)3), −4.33 (Si(CH3)2C(CH3)3),
17.96 (Si(CH3)2C(CH3)3), 17.99 (Si(CH3)2C(CH3)3), 25.75 (Si(CH3)2C(CH3)3), 25.79 (Si(CH3)2C(CH3)3),
27.92 (COOC(CH3)3), 36.35 (C-5′), 51.86 (C-6′), 66.97 (C-1”), 75.15 (C-2′), 75.24 (C-3′), 80.24 (C-4′),
82.98 (COOC(CH3)3), 91.20 (C-1′), 124.72 (d, JCF = 30.0 Hz, C-6), 128.22 (C-3”/C-4”), 128.26 (C-3”/C-4”),
128.51 (C-2”), 139.51 (C-5”), 140.65 (d, JCF = 238.3 Hz, C-5), 148.39 (C-2), 155.49 (d, JCF = 32.9 Hz, C-4).
19F NMR (376 MHz, CDCl3): δ [ppm] = −164.51. MS (ESI+): m/z = 738.5 [M + H]+, 760.4 [M + Na]+.
HRMS (ESI+): calcd.: 738.3612 [M + H]+, 760.3431 [M + Na]+, found: 738.3594, 760.3413. TLC: Rf =
0.53 (1:1, petroleum ether-EtOAc).
(6′S)-6′-N-Cbz-2′-deoxyuridinyl amino acid tert-butyl ester (39): Under strict exclusion of oxygen,
didehydro amino acid 35 (600 mg, 1.02 mmol) was dissolved in MeOH (35 mL). After addition of
(S,S)-Me-DUPHOS-Rh 37 (~15 mg, 21 µmol), the solution was stirred under an H2 atmosphere (~1
bar) at rt for 4 d. The reaction was monitored by 1H NMR spectroscopy. Additional catalyst 37 (~4
mg, 6 µmol) was added and stirring was continued for 2 d until the conversion of starting material 35
was complete. The solvent was evaporated under reduced pressure, and the resultant crude product
was purified by column chromatography (3:2, petroleum ether-EtOAc) to give 39 as a colorless foam
(562 mg, 93%). 1H NMR (500 MHz, CDCl3): δ [ppm] = 0.05 (s, 6H, Si(CH3)2C(CH3)3), 0.89 (s, 9H,
Si(CH3)2C(CH3)3), 1.43 (s, 9H, COOC(CH3)3), 1.93–2.02 (m, 1H, 5′-Ha), 2.03–2.11 (m, 1H, 2′-Ha), 2.20
(ddd, J = 14.2, 6.7, 2.9 Hz, 1H, 5′-Hb), 2.23–2.31 (m, 1H, 2′-Hb), 3.90–3.97 (m, 1H, 4′-H), 4.05 (dd, J = 10.8,
4.9 Hz, 1H, 3′-H), 4.41 (dd, J = 11.6, 6.7 Hz, 1H, 6′-H), 5.10 (s, 2H, 1”-H), 5.55 (d, J = 6.8 Hz, 1H, 6′-NH),
5.77 (d, J = 8.0 Hz, 1H, 5-H), 6.14 (dd, J = 6.1, 6.1 Hz, 1H, 1′-H), 7.27–7.39 (m, 5H, aryl-H), 7.54 (d, J =
8.0 Hz, 1H, 6-H), 8.92 (s, 1H, 3-NH). 13C NMR (126 MHz, CDCl3): δ [ppm] = −4.74 (Si(CH3)2C(CH3)3),
−4.48 (Si(CH3)2C(CH3)3), 18.03 (Si(CH3)2C(CH3)3), 25.79 (Si(CH3)2C(CH3)3), 28.06 (COOC(CH3)3),
36.14 (C-5′), 40.64 (C-2′), 52.23 (C-6′), 67.09 (C-1”), 74.92 (C-3′), 82.92 (COOC(CH3)3), 83.31 (C-4′), 85.63
(C-1′), 102.68 (C-5), 128.30, 128.37, 128.67 (C-3”, C-4”, C-5”, C-6”, C-7”), 136.38 (C-2”), 140.35 (C-6),
150.15 (C-2), 155.69 (Cbz-C=O), 163.29 (C-4), 170.61 (C-7′). HRMS (CI): calcd.: 590.2892 [M + H]+,
found: 590.2885. TLC: Rf = 0.25 (1:1, petroleum ether-EtOAc).
(6′S)-6′-N-Cbz-thymidinyl amino acid tert-butyl ester (40): Under strict exclusion of oxygen,
didehydro amino acid 36 (600 mg, 0.997 mmol) was dissolved in MeOH (35 mL). After addition of
(S,S)-Me-DUPHOS-Rh 37 (~20 mg, 28 µmol), the solution was stirred under an H2 atmosphere (~1
Molecules 2020, 25, 22 19 of 23
bar) at rt for 7 d. The reaction was monitored by 1H NMR spectroscopy. After complete conversion
of starting material 36, the solvent was evaporated under reduced pressure. The resultant crude
product was purified by column chromatography (1:1, petroleum ether-EtOAc) to give 40 as a colorless
foam (566 mg, 95%). 1H NMR (500 MHz, CDCl3): δ [ppm] = 0.06 (s, 6H, Si(CH3)2C(CH3)3), 0.88 (s,
9H, Si(CH3)2C(CH3)3), 1.43 (s, 9H, COOC(CH3)3), 1.97 (s, 3H, 7-H), 1.99–2.09 (m, 2H, 2′-Ha, 5′-Ha),
2.14–2.20 (m, 1H, 5′-Hb), 2.22 (ddd, J = 13.5, 6.5, 4.3 Hz, 1H, 2′-Hb), 3.92–3.97 (m, 1H, 4′-H), 4.07 (ddd, J
= 6.5, 4.3, 4.3 Hz, 1H, 3′-H), 4.42 (dd, J = 11.8, 7.1 Hz, 1H, 6′-H), 5.10 (s, 2H, 1”-H), 5.54 (d, J = 6.7 Hz,
1H, 6′-NH), 6.18 (dd, J = 6.5, 6.5 Hz, 1H, 1′-H), 7.29–7.36 (m, 5H, aryl-H), 7.37 (s, 1H, 6-H), 8.53 (brs, 1H,
3-NH). 13C NMR (126 MHz, CDCl3): δ [ppm] = −4.71 (Si(CH3)2C(CH3)3), −4.47 (Si(CH3)2C(CH3)3),
12.46 (C-7), 18.05 (Si(CH3)2C(CH3)3), 25.18 (Si(CH3)2C(CH3)3), 28.06 (COOC(CH3)3), 36.26 (C-5′), 40.39
(C-2′), 52.16 (C-6′), 67.06 (C-1”), 75.11 (C-3′), 82.89 (COOC(CH3)3), 83.26 (C-4′), 85.27 (C-1′), 111.33
(C-5), 128.26, 128.37, 128.68 (C-3”, C-4”, C-5”, C-6”, C-7”), 136.00 (C-6), 136.41 (C-2”), 150.18 (C-2),
155.65 (Cbz-C=O), 163.74 (C-4), 170.65 (C-7′). HRMS (CI): calcd.: 604.3049 [M + H]+, found: 604.3029.
TLC: Rf = 0.30 (1:1, petroleum ether-EtOAc).
(6′S)-5,6-dihydrouridinyl amino acid tert-butyl ester (42): (6′S)-6′-N-Cbz-uridinyl amino acid
tert-butyl ester 41 [31] (100 mg, 0.139 mmol) was dissolved in i-PrOH (20 mL) and stirred over molecular
sieve (3 Å) at rt for 15 min. Pd black (130 mg, 1.22 mmol) was added and the reaction mixture was
stirred under an H2 atmosphere (~1 bar) at rt for 4 h. After filtration through a syringe filter and
washing the filter with i-PrOH (50 ◦C, 45 mL), the solvent of the combined filtrates was evaporated
under reduced pressure to give 42 as a colorless foam (82 mg, 96%). 1H NMR (300 MHz, CDCl3): δ
[ppm] = 0.06 (s, 3H, Si(CH3)2C(CH3)3), 0.07 (s, 3H, Si(CH3)2C(CH3)3), 0.08 (s, 3H, Si(CH3)2C(CH3)3),
0.09 (s, 3H, Si(CH3)2C(CH3)3), 0.90 (s, 9H, Si(CH3)2C(CH3)3), 0.91 (s, 9H, Si(CH3)2C(CH3)3), 1.46 (s,
9H, COOC(CH3)3), 1.68 (ddd, J = 13.9, 9.4, 7.1 Hz, 1H, 5′-Ha), 2.12 (ddd, J = 13.9, 6.0, 2.6 Hz, 1H,
5′-Hb), 2.63—2.69 (m, 2H, 5-H), 3.29–3.40 (m, 1H, 6-Ha), 3.49 (dd, J = 6.3, 6.3 Hz, 1H, 6-Hb), 3.56 (dd, J
= 7.1, 7.0 Hz, 1H, 6′-H), 3.74 (dd, J = 5.7, 4.6 Hz, 1H, 3′-H), 4.01 (ddd, J = 9.4, 5.7, 2.6 Hz, 1H, 4′-H),
4.14 (dd, J = 4.6, 4.0 Hz, 1H, 2′-H), 5.59 (d, J = 4.0 Hz, 1H, 1′-H), 7.61 (brs, 1H, 3-NH). 13C NMR (126
MHz, CDCl3): δ [ppm] = −4.49 (Si(CH3)2C(CH3)3), −4.40 (Si(CH3)2C(CH3)3), −4.38 (Si(CH3)2C(CH3)3),
−4.00 (Si(CH3)2C(CH3)3), 18.15 (Si(CH3)2C(CH3)3), 18.24 (Si(CH3)2C(CH3)3), 25.93 (Si(CH3)2C(CH3)3),
26.02 (Si(CH3)2C(CH3)3), 28.16 (COOC(CH3)3), 31.29 (C-5), 38.47 (C-5′), 38.70 (C-6), 53.62 (C-6′), 73.52
(C-2′), 76.14 (C-3′), 80.81 (C-4′), 81.69 (COOC(CH3)3), 91.64 (C-1′), 152.17 (C-2), 169.44 (C-4), 173.97
(C-7′). HRMS (CI): calcd.: 588.3495 [M + H]+, found: 588.3488.
N-Cbz-protected 5,6-dihydrouridine derivative (44): Nucleosyl amino acid ester 42 (100 mg,
0.170 mmol) was dissolved in THF (14 mL) and aldehyde 43 [24,34] (70 mg, 0.22 mmol) was added.
The reaction mixture was stirred over molecular sieve (3 Å) at rt for 23 h. NaBH(OAc)3 (80 mg, 0.39
mmol) and Amberlyst 15TM (14 mg, 44 µmol) were added and stirring was continued at rt for 22 h.
The reaction mixture was filtered and the residue was washed with EtOAc (150 mL). The combined
filtrates were washed with sat. NaHCO3 solution (100 mL) and brine (50 mL). The aqueous layer
was extracted with EtOAc (3 × 100 mL). The combined organics were dried over Na2SO4 and the
solvent was evaporated under reduced pressure. The resultant crude product was purified by
column chromatography (98:2, CH2Cl2-MeOH) to give 44 as a colorless solid (93 mg, 58%). 1H NMR
(500 MHz, CD3OD): δ [ppm] = 0.11 (s, 3H, Si(CH3)2C(CH3)3), 0.12 (s, 3H, Si(CH3)2C(CH3)3), 0.13
(s, 3H, Si(CH3)2C(CH3)3), 0.14 (s, 3H, Si(CH3)2C(CH3)3), 0.84–0.91 (m, 6H, Leu-5-H), 0.92 (s, 9H,
Si(CH3)2C(CH3)3), 0.93 (s, 9H, Si(CH3)2C(CH3)3), 1.49 (s, 9H, COOC(CH3)3), 1.53 (dd, J = 7.2, 7.2 Hz,
2H, Leu-3-H), 1.63–1.72 (m, 3H, 2”-H, Leu-4-H), 1.78 (ddd, J = 13.4, 11.2, 4.9 Hz, 1H, 5′-Ha), 1.99 (ddd, J
= 13.4, 9.6, 2.7 Hz, 1H, 5′-Hb), 2.51–2.58 (m, 1H, 1”-Ha), 2.60–2.67 (m, 3H, 1”-Hb, 5-H), 3.18–3.36 (m, 2H,
6′-H, 3”-Ha), 3.39 (ddd, J = 12.9, 6.6, 6.6 Hz, 1H, 6-Ha), 3.47 (ddd, J = 12.9, 6.7, 6.7 Hz, 1H, 6-Hb), 3.56
(ddd, J = 8.1, 4.4, 4.4 Hz, 1H, 3”-Hb), 3.85 (dd, J = 4.8, 4.8 Hz, 1H, 3′-H), 3.88–3.94 (m, 1H, 4′-H), 4.04–4.14
(m, 1H, Leu-2-H), 4.25 (dd, J = 4.8, 4.6 Hz, 1H, 2′-H), 5.09 (s, 2H, 1”′-H), 5.77 (d, J = 4.6 Hz, 1H, 1′-H),
7.25–7.39 (m, 5H, aryl-H). 13C NMR (126 MHz, CD3OD): δ [ppm] = −4.36 (Si(CH3)2C(CH3)3), −4.34
(Si(CH3)2C(CH3)3), −4.13 (Si(CH3)2C(CH3)3), −3.93 (Si(CH3)2C(CH3)3), 18.90 (Si(CH3)2C(CH3)3), 18.94
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(Si(CH3)2C(CH3)3), 23.37 (Leu-C-5), 23.46 (Leu-C-5), 25.99 (Leu-C-4), 26.41 (Si(CH3)2C(CH3)3), 26.48
(Si(CH3)2C(CH3)3), 28.44 (COOC(CH3)3), 29.97 (C-2”), 31.93 (C-5), 37.46 (C-5′), 38.09 (C-6), 39.00 (C-3”),
42.22 (Leu-C-3), 46.02 (C-1”), 55.23 (Leu-C-2), 60.41 (C-6′), 67.71 (C-1”′), 74.14 (C-2′), 77.15 (C-3′), 81.10
(C-4′), 83.24 (COOC(CH3)3), 91.77 (C-1′), 128.85 (C-3”′, C-7”′), 129.09 (C-5”′), 129.50 (C-4”′, C-6”′),
138.20 (C-2”′), 154.93 (C-2), 158.39 (Cbz-C=O), 172.49 (C-4), 175.67 (C-7′), 181.44 (Leu-C-1). HRMS
(ESI+): calcd.: 892.5282 [M + H]+, found: 892.5261.
5,6-Dihydrouridine derivative (45): N-Cbz-protected 5,6-dihydrouridine derivative 44 (51 mg, 57
µmol) was dissolved in MeOH (10 mL) and Pd/C (10%, 3.6 mg, 3.4 µmol Pd) was added. The reaction
mixture was stirred under an H2 atmosphere (~1 bar) at rt for 2 h. After filtration through a syringe filter
and washing the filter with EtOAc (50 ◦C, 20 mL), the solvent of the combined filtrates was evaporated
under reduced pressure to give 45 as a colorless solid (42 mg, quant.). 1H NMR (500 MHz, CD3OD): δ
[ppm] = 0.11 (s, 3H, Si(CH3)2C(CH3)3), 0.12 (s, 3H, Si(CH3)2C(CH3)3), 0.13 (s, 3H, Si(CH3)2C(CH3)3),
0.14 (s, 3H, Si(CH3)2C(CH3)3), 0.89–0.96 (m, 6H, Leu-5-H), 0.92 (s, 9H, Si(CH3)2C(CH3)3), 0.94 (s, 9H,
Si(CH3)2C(CH3)3), 1.41–1.55 (m, 2H, Leu-3-H), 1.49 (s, 9H, COOC(CH3)3), 1.64–1.72 (m, 3H, 2”-H,
Leu-4-H), 1.76 (ddd, J = 13.9, 10.8, 4.9 Hz, 1H, 5′-Ha), 1.96–2.02 (m, 1H, 5′-Hb), 2.52 (ddd, J = 11.6, 7.0,
7.0 Hz, 1H, 1”-Ha), 2.59–2.68 (m, 3H, 5-H, 1”-Hb), 3.19–3.30 (m, 2H, 6′-H, 3”-Ha), 3.41 (ddd, J = 13.6, 6.8,
6.8 Hz, 1H, 6-Ha), 3.49 (ddd, J = 13.6, 6.8, 6.8 Hz, 1H, 6-Hb), 3.85 (dd, J = 4.8, 4.8 Hz, 1H, 3′-H), 3.88–3.93
(m, 1H, 4′-H), 4.04–4.14 (m, 1H, Leu-2-H), 4.24 (dd, J = 4.8, 4.5 Hz, 1H, 2′-H), 5.76 (d, J = 4.5 Hz, 1H,
1′-H). 13C NMR (126 MHz, CD3OD): δ [ppm] = −4.36 (Si(CH3)2C(CH3)3), −4.35 (Si(CH3)2C(CH3)3),
−4.13 (Si(CH3)2C(CH3)3), −3.92 (Si(CH3)2C(CH3)3), 18.90 (Si(CH3)2C(CH3)3), 18.93 (Si(CH3)2C(CH3)3),
22.58 (Leu-C-5), 23.41 (Leu-C-5), 25.92 (Leu-C-4), 26.41 (Si(CH3)2C(CH3)3), 26.48 (Si(CH3)2C(CH3)3),
28.46 (COOC(CH3)3), 30.43 (C-2”), 31.95 (C-5), 38.17 (C-5′), 38.25 (C-6), 38.85 (C-3”), 45.71 (Leu-C-3),
46.16 (C-1”), 54.68 (Leu-C-2), 60.94 (C-6′), 74.24 (C-2′), 77.16 (C-3′), 81.13 (C-4′), 82.77 (COOC(CH3)3),
91.61 (C-1′), 154.93 (C-2), 172.49 (C-4), 174.97 (C-7′), 178.16 (Leu-C-1). MS (ESI+): calcd.: 758.49 [M +
H]+, found: 758.57.
4.2. Overexpression of MraY from S. Aureus
The overexpression of MraY was performed as described before [39,41,49].
4.3. Fluorescence Based MraY Assay
The assay was performed as described before [39,41,49]. Measured data and inhibition curves are
shown in the Supplementary Materials Figures S1–S4.
5. Conclusions
In summary, we report valuable new SAR insights for synthetic analogues of muraymycin
antibiotics with structural variations in the nucleoside core unit. For this purpose, we have synthesized
four novel muramycin analogues 13–16. The modular preparation of 13–15 demonstrated the efficiency
of a recently established bipartite approach employing a solid phase-supported protocol for the
construction of the peptide moiety [42]. Furthermore, it was shown that our previously reported
route towards 5’-defunctionalized nucleosyl amino acids [31] is also applicable for structurally
modified nucleosides.
By in vitro evaluation of 13–16 as inhibitors of the bacterial target protein MraY, it was found that
the introduction of substituents in the 5-position of the pyrimidine nucleobase led to a drastic loss of
inhibitory potency towards MraY. In contrast, the removal of nucleobase aromaticity (by reduction of
the uracil C5-C6 double bond) only resulted in a ca. tenfold decrease in activity. The formal removal
of the 2′-hydroxy group, however, led to a retention of inhibitory activity, thus demonstrating that
modifications of the ribose moiety might be well-tolerated. These results were in good agreement
with previous X-ray crystallographic studies on the interaction of naturally occurring muraymycin
D2 7 with MraY. This indicates that such X-ray crystal structures of MraY-inhibitor complexes can
be highly useful for the structure-based design of new MraY inhibitors. In this work, only four
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nucleoside-modified muraymycin analogues were studied, thus limiting the possibility to derive
robust general instructions for the future design of muraymycin analogues from the reported data.
Nevertheless, the obtained SAR insights strongly suggest that nucleobase modifications should be
avoided, while the ribose moiety appears to be a good choice for the introduction of novel structural
variations. This may even include lipophilic moieties in order to improve the bacterial cellular uptake
of otherwise rather polar muraymycin analogues, thus providing congeners with improved activities
in cellulo. Such development of synthetic muraymycin analogues towards potential antibacterial drug
candidates is currently on the way in our laboratories.
Supplementary Materials: The following are available online, data from the MraY assays, copies of NMR spectra
and Figures S1–S5.
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